Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview by Fischer, Peter M.
Fischer, Peter M. (2017) Approved and experimental 
small-molecule oncology kinase inhibitor drugs: a mid-
2016 overview. Medicinal Research Reviews, 37 (2). pp. 
314-367. ISSN 1098-1128 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/37903/1/Fischer_PM_Med_Res_Rev_2016_ePrint.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
 1 
Approved and experimental small-molecule 
oncology kinase inhibitor drugs: a mid-2016 
overview 
Peter M. Fischer 
School of Pharmacy and Centre for Biomolecular Sciences, University of 
Nottingham, Nottingham NG7 2RD, UK 
Abstract. Kinase inhibitor research is a comparatively recent branch of me-
dicinal chemistry and pharmacology and the first small-molecule kinase in-
hibitor, imatinib, was approved for clinical use only 15 years ago. Since 
then, 33 more kinase inhibitor drugs have received regulatory approval for 
the treatment of a variety of cancers and the volume of reports on the 
discovery and development of kinase inhibitors has increased to an extent 
where it is now difficult –even for those working in the field– easily to keep 
an overview of the compounds that are being developed, as currently there 
are 231 such compounds, targeting 38 different protein and lipid kinases 
(not counting isoforms), in clinical use or under clinical investigation. The 
purpose of this review is thus to provide an overview of the biomedical 
rationales for the kinases being targeted on the one hand, and the design 
principles, as well as chemical, pharmacological, pharmaceutical, and toxi-
cological kinase inhibitor properties, on the other hand. Two issues that are 
especially important in kinase inhibitor research, target selectivity and drug 
resistance, as well as the underlying structural concepts, are discussed in 
general terms and in the context of relevant kinases and their inhibitors. 
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Introduction 
Kinases are now one of the most important drug development target classes in several 
therapeutic indications, but until very recently all kinase inhibitors that were approved for 
clinical use were anticancer drugs, with the exception of fasudil, a (diazepanesulfonyl)iso-
quinoline ROCK inhibitor (for protein kinase nomenclature refer to Table S1).1 Fasudil has 
been approved for some years in Japan for the treatment of certain cardiovascular indica-
tions2 but even this agent –and ROCK inhibitors in general– may in fact also have potential 
uses in oncology.3 However, the situation changed with the U.S. Food and Drug Admin-
istration (FDA) approval in 2012 of the pyrrolopyrimidine JAK inhibitor tofacitinib for the 
treatment of rheumatoid arthritis.4 Again JAK inhibitors are also relevant in cancer, as we 
shall see later. At the time it was expected that the first kinase inhibitor approval outside 
oncology would act as a watershed and that pharmaceutical companies would accelerate 
kinase inhibitor development for a range of different therapeutic indications. In fact kinase 
inhibitors are undergoing clinical development in inflammatory, cardiovascular, neuro-
degenerative, liver, and metabolic diseases5 but since the approval of tofacitinib there has 
been only one additional approval outside oncology: nintedanib, a multi-targeted kinase 
inhibitor (MTKI), in idiopathic pulmonary fibrosis (IPF).6 Interestingly this compound was 
also approved in the European Union for lung cancer patients with advanced adenocarci-
noma after first-line chemotherapy. Here we shall confine our discussion to kinase inhibi-
tors in oncology, not only approved agents (Figure 1), but all compounds currently under-
going clinical development. 
According to an analysis of new anticancer therapeutics that entered the clinic during the 
period 1990-2006, kinase inhibition was the most prevalent mode of action of experimental 
agents, whereas previously interference with DNA replication was the most common mech-
anism.7 A different analysis of new clinical oncology agents during a similar period (1995-
2007) noted that while clinical development attrition was high (82%) overall, kinase inhib-
itors performed significantly better (53% attrition).8 
Only a few years ago it was easy for those working in the field to keep track of the kinase 
inhibitor oncology drugs under development but the sheer number of agents that have 
recently entered clinical studies now renders this difficult. The main purpose of the present 
review is therefore to provide an up-to-date summary of some of approved and experi-
mental (as verified in relevant publicly accessible literature, corporate disclosures, and 
https://clinicaltrials.gov/) kinase inhibitor cancer drugs. Salient points regarding kinase 
inhibitor targets, selectivity, medicinal chemistry, pharmacology, and toxicology will be 
discussed. Biological agents, including antibodies and antisense oligonucleotides, are not 
included but the focus is on small-molecule agents. 
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Selectivity 
Following the success with the first approved small-molecule kinase inhibitor anticancer 
drug, imatinib (Figure 1),9 especially in the treatment of chronic myelogenous leukaemia 
(CML), highly specific targeted kinase inhibitors rapidly became a desirable goal in oncol-
ogy drug discovery. However, demonstration of clear-cut clinical efficacy has been much 
more elusive with a range of other experimental kinase inhibitor drugs, and this situation 
has led to the on-going dispute about selective versus so-called multi-targeted agents. 
The question is whether ‘magic bullets’ are preferable to ‘magic shotguns’10 and arises not 
so much because one might be superior to the other, but because upon closer examination 
even the most carefully designed small-molecule kinase inhibitors often inadvertently turn 
out to be multi-targeted. In the early days of kinase inhibitor development it was not 
possible to profile the kinase selectivity of candidate molecules extensively, and unex-
pected kinase targets were frequently discovered for drugs late in the development pro-
cess. This situation has changed with the advent of kinase panel11 and chemical prote-
omics12 technologies that permit kinome-wide analysis of candidate molecules. 
Nevertheless, multi-targeted agents are frequently more efficacious than selective ones,13 
although this may be due to selective drugs lacking efficacy because they block targets 
that are inappropriate per se or inappropriate for a specific cancer. Furthermore, network 
models suggest that partial inhibition of a small number of targets can be more efficient 
than the complete inhibition of a single target.14 Certainly the task of devising a kinase 
inhibitor that exclusively inhibits a range of predetermined kinases –which may not neces-
sarily be structurally related– would appear to be formidable. Although strategies for the 
rational design of multi-targeted agents by multiple structure-based design and pharma-
cophore combination15,16 have been described, these have not yet been implemented 
widely for the design of kinase inhibitors with predetermined multiple selectivity. 
Active versus inactive kinases. Because the vast majority of small-molecule kinase in-
hibitors target the ubiquitous ATP-binding site, target selectivity represents the biggest 
challenge for kinase inhibitor drug design and development. Protein and lipid kinases cat-
alyse the transfer of the γ-phosphoryl group of ATP to their specific macromolecular sub-
strates. This requires an architectural arrangement of the kinase to allow simultaneous 
binding of both substrates and positioning of the catalytic residues for productive phos-
phoryl-transfer. For protein kinases this canonical arrangement can be illustrated using 
PKA as an example (Figure 2). ATP is bound in a cleft between the N- and C-lobes of the 
kinase. These lobes are connected by the hinge region, which contains the so-called gate-
keeper residue. The adenine portion of ATP forms H-bonds with the main-chain peptide 
bonds of the two hinge residues distal to the gatekeeper. The activation (A) loop adopts a 
conformation that supports binding of the macromolecular substrate and in which the side 
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chain of the Asp residue of the conserved DFG motif is positioned towards the ATP γ-
phosphate (DFG in). Furthermore, the active (i.e. catalytically competent) kinase architec-
ture is characterised by a near-linear arrangement of the regulatory (R) spine, which is 
composed of five residues (R0–R4) that interlock through H-bonding (R0–R1), CH–π (R1–
R2–R3), and hydrophobic (R3–R4) interactions. Distortion of the linear spine, which con-
tains residues from both the N- (R3 and R4) and C-lobes (R0, R1, and R2), is characteristic 
of inactive kinase architectures and can result from tilting of the kinase lobes about the 
hinge, by conformational preferences of the A-loop as a result of its phosphorylation status, 
or movement of the αC-helix or the catalytic (C) loop. 
Classification of kinase inhibitors. Kinase inhibitors are classified using various criteria 
and several classification systems are in use. Here we shall use the integrated system 
recently proposed by Roskoski:17 Type-I inhibitors bind to the active kinase conformation 
with DFG-Asp in (towards the ATP-binding site), the αC-helix in, and with the R-spine in a 
linear configuration. Type-I½ inhibitors bind to kinases with an inactive (distorted R-spine) 
conformation with DFG-Asp in but αC-helix out. Type-II inhibitors also bind to inactive 
kinase conformations, but with DFG-Asp out. By division of the ATP-binding cleft into a 
front cleft and a back cleft (see below), type-I and type-II inhibitors can be further sepa-
rated into A and B subtypes, where subtype A extends into the back cleft and subtype B 
does not. Allosteric inhibitors of type III bind in the cleft between the small and large 
kinase lobes but adjacent to the ATP-binding pocket, whereas type-IV inhibitors bind out-
side of the cleft and the phosphoryl-acceptor region. Allosteric ligands that span two re-
gions of the protein kinase domain are type-V inhibitors. Compounds that form covalent 
adducts with a kinase are type-VI inhibitors. 
X-ray crystal structures of complexes with type-I inhibitors generally show an active-like 
kinase conformation with the inhibitors bound at the same site as ATP but making contacts 
with kinase residues beyond those involved in binding of ATP. Such inhibitors also fre-
quently recapitulate the hinge H-bonding pattern observed with ATP, using a variety of 
heterocyclic systems.18 Whereas binding of ATP does not usually depend on interactions 
with the gatekeeper, binding of inhibitors generally does. In type-I inhibitors selectivity 
arises from interactions of the inhibitor with non-conserved residues at the front (solvent-
exposed; hydrophobic pocket I) and the back (towards gatekeeper; hydrophobic pocket 
II) of the binding cleft. 
Type-II inhibitors are still ATP-competitive and bind to the ATP-binding pocket in a similar 
manner as type-I inhibitors but they bind to kinases with inactive architectures (disrupted 
R spine). These architectures possess altered A-loop conformations, where the DFG Asp 
residue side chain points away from the ATP γ-phosphate (DFG out) and the DFG Phe 
residue (R2) projects into the ATP-binding site. As a result, the R spine is disrupted and 
the kinase is not catalytically competent. Such a movement of the R2 side chain opens up 
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a new binding pocket (sometimes called the back cleft) beyond the gatekeeper and towards 
the αC-helix. Type-II inhibitors, which are typically larger than type-I inhibitors, usually 
extend into this pocket, which differs significantly between kinases. 
Selectivity based on kinase inhibition potency. Inhibitor selectivity between kinase 
pairs is commonly expressed as a ratio (Figure 3a; selectivity index 1, SI1) between 
measures of potency, such as half-maximal inhibition values (IC50), inhibition constants 
(Ki), or dissociation constants (Kd). Biochemical kinase activity assays are generally used 
to determine IC50 values but it is important to remember that selectivity ratios for ATP-
competitive inhibitors based on IC50 values can be misleading unless kinase assays are 
performed at ATP concentrations that give half-maximal reaction velocities for the kinases 
in question (i.e. [ATP] = KM (ATP)). It is known that the ATP Michaelis constants (KM (ATP)) for 
different kinases vary over a range of 3 orders of magnitude from low µM to mM values.19 
This is important because in cells, where the ATP concentration is typically as high as 1-5 
mM, the potency of an inhibitor against a given kinase is highly dependent on the KM (ATP) 
of that kinase. For this reason Ki values are more useful for selectivity measurements, 
since these take into account KM (ATP): Ki = IC50 / (1 + ([ATP] / KM (ATP))).20 Kd values are 
typically determined using biophysical binding assays rather than functional kinase assays. 
Provided assay conditions are similar (concentrations of protein and substrates) then Kd 
and Ki values are also numerically similar. 
It is sometimes stated that type-II inhibitors are not ATP competitive and that for this 
reason the drop-off in cellular potency from biochemical potency is frequently smaller than 
is the case for type-I inhibitors.21 This is not entirely correct, since inactive forms of kinases 
can still bind ATP, although the difference in KM (ATP) between inactive and activated (phos-
phorylated) kinase forms can be large.19 The ratio of biochemical and cellular potency of a 
kinase inhibitor will therefore depend on whether it competes with ATP for the active or an 
inactive state of the target kinase, and in the latter case on the KM (ATP) of the inactive state. 
Regardless of inhibition mode, the relationship between biochemical and cellular potency 
is of course also affected by factors such as solubility, protein binding, and membrane 
permeability. 
Selectivity based on receptor occupancy. For kinase inhibitor drugs we are interested 
not so much in selectivity based on differential kinase affinity under equilibrium conditions 
(SI1), but in selectivity under physiological conditions in vivo. Here we need to take into 
account that the magnitude of physiological responses is proportional to the amount of 
inhibitor bound by a particular kinase over time. To assess true selectivity of kinase inhib-
itors it is therefore more useful to look at fractional kinase (receptor) occupancy as a func-
tion of time (fot). Based on this we can formulate a second selectivity index (Figure 3a; 
SI2). 
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For a type-I kinase inhibitor that reversibly binds a kinase by mechanism A, fot depends 
on ligand concentration and Kd as shown in Figure 3a. To illustrate the relationship between 
SI1 and SI2, let us assume that we have kinase inhibitors that all bind a particular on-target 
kinase with a Kd value of 10 nM but that bind an undesirable (leading to toxicity) off-target 
kinase with Kd values of 50 nM (SI1 = 5), 250 nM (SI1 = 25), 1 µM (SI1 = 100), and 10 µM 
(SI1 = 1,000), respectively. If we assume that these hypothetical kinase inhibitors have 
identical pharmacokinetic profiles and are dosed repeatedly so as to achieve continuous 
exposure, measured as the concentration of free drug fraction at steady state (Cssf), then 
we can substitute Cssf for [L]t in the expression for fot and evaluate SI2 as a function of Cssf. 
This analysis (Figure 3b) shows that at Cssf = Kd (on-target) = 10 nM we have approximately 
50% on-target receptor occupancy. At that Cssf value we have SI2 values of 3, 13, 50, and 
500 for the inhibitors with SI1 values of 5, 25, 100, and 1,000, respectively. Depending on 
how physiological responses are coupled to on-target kinase occupancy, we may require 
much higher fo to achieve efficacy. If 90% occupancy is required (foon-target = 0.9, Cssf = 90 
nM), then the SI2 values for our inhibitors are 1.4 (SI1 = 2.5), 3.4 (SI1 = 25), 11 (SI1 = 
50), and 100 (SI1 = 1,000), respectively. Depending on how off-target kinase occupancy 
is coupled to toxicity, the drop-off from SI1 to SI2 may be smaller or larger but the rela-
tionship between selectivity in terms of binding versus occupancy as a function of Cssf 
clearly shows that an inhibitor with an SI1 value of < 100 is unlikely to provide a useful 
margin between on- and off-target activities in vivo. 
Selectivity based on residence time. High-affinity kinase inhibitors, especially those of 
type II, frequently exhibit slow binding kinetics. This is due to induced-fit binding, where 
the kinase undergoes a time-dependent change from a conformation R to a conformation 
R*, where the latter has higher affinity for the ligand L than the former (Figure 3a; mech-
anism B). Here dissociation (off-rate) and residence time are not defined by a single rate 
constant as in mechanism A, but by a composite of rate constants, where k4 (and some-
times k2) are limiting for dissociation. For inhibitors that bind kinases in inactive-like con-
formations, mechanism C is sometimes invoked, especially when these inhibitors selec-
tively bind the kinase in its A-loop non-phosphorylated state. There are currently insuffi-
cient kinetic data to distinguish clearly between inhibitors that act by mechanisms B and 
C, however.22 
In any case, the situation often arises where an inhibitor exhibits kinase residence time 
that is significant in comparison to its in vivo elimination half-life. Under these conditions 
receptor occupancy can be maintained at levels leading to pharmacological responses even 
after a drug has been largely eliminated from systemic circulation. Under these circum-
stances we need to take the dynamics of binding into account when assessing selectivity. 
To illustrate this point let us assume that we have a kinase inhibitor that interacts with 3 
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target kinases and that the rate constants k1 (1 × 108 M-1 s1, i.e. 10-fold below the diffu-
sional limit), k2 (1 s-1), and k3 (6 × 10-3 s-1) are identical in each case, and that only k4 
varies: 8.5 × 10-3 s-1 (target 1), 2.8 × 10-4 s-1 (target 2), and 1.26 × 10-5 s-1 (target 3), 
i.e. typical values for type-I, type-II, and covalent reversible type-VI inhibitors.17,23 With 
these values we have residence times τ of 2 min (target 1), 1 h (target 2), and 22 h (target 
3). If we further assume that the inhibitor was dosed orally once, reaching a maximum 
plasma concentration (Cmax) of 10 µM and being eliminated with a half-life of 3 h, then we 
can calculate free plasma levels, as well as fot with respect to the 3 targets, as a function 
of time as shown (Figure 3c). This analysis reveals that here selectivity is not driven by 
apparent affinity under equilibrium, but by residence time. Thus > 50% receptor occupancy 
is maintained for up to 12 h (target 1), 24 h (target 2), and 36 h (target 3). For targets 2 
and 3, significant receptor occupancy persists at a time when plasma levels would be un-
detectable using conventional bioanalysis methods (24 h, Cf = 4.2 × 10-10 M). Because the 
inhibitor dissociates from target 3 much more slowly than for targets 1 and 2, it can be 
expected to be functionally selective for target kinase 3. Again the exact situation will 
depend on the magnitude and duration of receptor occupancy required to elicit physiolog-
ical responses from the 3 targets, but it is clear that residence time is important in terms 
of selectivity and should be considered in the drug discovery process.24 
Target validity 
It is important to remember that the pioneer kinase inhibitor drug imatinib itself is not 
mono-selective for BCR-ABL, the oncogenic kinase uniquely present in chronic mye-
logenous leukaemia (CML), but also inhibits a range of other kinases with high potency. 
Clearly the therapeutic effectiveness of imatinib in CML is not principally a result of drug 
selectivity, but the vital dependence of CML cells on BCR-ABL kinase activity. So for the 
narrow versus broad drug selectivity discussion to make any sense, we need to consider 
target validity. 
If pharmacological modulation of a specific cellular component is sufficient to eradicate a 
diagnostically distinct cancer type, then surely an agent highly selective for that target 
should be preferable to a more promiscuous one on basic pharmacological grounds. If, on 
the other hand, the viability of a particular cancer type only appears susceptible to inter-
ference with two or more aberrant components, then multi-targeted agents would seem 
to be called for. Because we want to devise new cancer therapies that are inherently less 
toxic than conventional chemotherapies, the important thing is specificity for cancerous 
cells rather than inherent target selectivity. 
If we accept the premise that at least for some cancer indications modulation of multiple 
targets is necessary to achieve the desired therapeutic effect, then the question that poses 
itself is whether it would be better to employ an appropriate cocktail of highly selective 
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drugs or a single multi-targeted drug.25,26 Considering the complexity of human cancers, 
one would expect that the availability of a range of highly targeted agents would allow a 
more effective and modular approach to personalised therapy than multi-targeted agents. 
However, combination therapies are prone to dosing errors and drug–drug interactions.27 
Furthermore, highly targeted drugs by definition will not find broad chemotherapeutic ap-
plication but will only work in the (perhaps small) subset of cancers that possess the spe-
cific targeted molecular lesion, whereas multi-targeted drugs may find wider therapeutic 
use, i.e. they may be preferable commercial propositions for pharmaceutical companies.  
As it turns out, the main clinical indication for imatinib, CML, is unusual since most cancers, 
especially non-haematological tumours, including e.g. common epithelial neoplasms of the 
lung, breast, colon, and prostate, display a much more complex transformed genotype 
than CML and may lack the critical vulnerability centred on a single cellular component 
characteristic of early-stage CML. In fact mouse models suggest that the BCR-ABL trans-
location is the only genetic abnormality required to cause CML.28 It thus follows that 
imatinib probably represents an exception rather than a new paradigm in the area of kinase 
inhibitors.29 
However, target validation work in several areas suggests that there are probably many 
other cancers that may also possess therapeutic Achilles heels. Typically this situation 
arises as a result of oncogene addiction, i.e. the apparently paradoxical dependence of a 
tumour cell for sustained proliferation and survival on a single oncogenic pathway or pro-
tein, despite the presence of numerous genetic alterations.30 A number of such oncogene 
addictions have been identified and frequently the relevant oncogene products are ki-
nases.31,32 Such kinases are attractive as cancer drug targets, and several are now being 
targeted with experimental drugs, e.g. BRAF in melanoma, HER2 in breast cancer, HER1 
in non-small cell lung cancer (NSCLC), MET in gastric cancer, and ARK in colon cancer. 
However, unlike in the case of CML, these addictions are not usually present in all cancers 
of a particular histological type, but the potentially responsive cancers need to be identified 
by examination of appropriate biomarkers. 
Drug resistance 
Although not themselves mutagenic like many conventional chemotherapy agents, kinase 
inhibitor drugs, just like most anticancer drugs, are nevertheless prone to both intrinsic 
and acquired resistance. The manifestation of drug resistance in at least a proportion of 
cases involves direct mutation of the target kinase in such a way that function is preserved, 
while inhibition by the drug is circumvented. Although it remains unclear how these muta-
tions are caused, it is likely that genetic selection for insensitive target kinase mutants 
under the influence of the kinase inhibitor drug plays a role. This phenomenon was first 
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observed with imatinib and is in part responsible for the current emphasis on MTKIs, which 
may not be vulnerable to the same extent to this selection pressure.33 
In the case of the HER1 inhibitors gefitinib and erlotinib, which are used for the treatment 
of NSCLC with certain somatic mutations in the HER1 Tyr kinase or with amplified wild-
type HER1, it has also been observed that all patients eventually develop resistance, either 
through a secondary HER mutation T790M in about half of all cases, by MET oncogene 
amplification, or via other mechanisms.34 The HER1 T790M mutation concerns the gate-
keeper residue (Thr in most Tyr kinases), which is not required for the binding of the 
natural cofactor ATP, but which is almost invariably involved in the recognition of ATP-
antagonist kinase inhibitors. Resistance to HER2 inhibitors in breast cancer are also fre-
quent and also develops through multiple mechanisms but unlike for HER1 inhibitors, e.g. 
lapatinib resistance due to the HER2 gatekeeper T798I mutation, appears to be less prev-
alent.35 Resistance mutations corresponding to those observed with HER Tyr kinase inhib-
itors are known to be important in the case of many other kinases and their inhibitors, as 
we shall see later. 
It has long been known that cancer cells can develop drug resistance much more rapidly 
than would be predicted from the rates of conventional mutation, by differential utilisation 
of the genome, while normal cells in the same organism remain sensitive. There is now 
much evidence that not only point mutations, but also deletions, translocations, amplifica-
tions, epigenetic changes, and even altered microRNA levels, can generate cancer cell 
progeny tolerant to individual or multiple drugs.36 It is also now believed that clonal kary-
otype alterations are generated auto-catalytically by cancer-specific aneuploidy and that 
these specific chromosomal alterations cause drug resistance by changing the stoichiome-
try and integrity of multigenic transcriptomes.37 Even in the case of imatinib over half of 
all resistance cases are associated with clonal karyotype alterations rather than kinase 
mutations.38 
Toxicology 
For the discussion of kinase inhibitor toxicology we need to return to the question of se-
lectivity. Provided a hypothetical mono-selective kinase inhibitor anticancer drug does not 
give rise to toxic metabolites, one would expect such a compound to possess a clean tox-
icology profile. Obviously this will only be the case, however, if on-target effects in tissues 
other than the tumour can be tolerated. Again we can use the pioneer kinase inhibitor drug 
imatinib to illustrate this point. Although one of the targets of imatinib, BCR-ABL, is 
uniquely present in transformed granulocytes as a result of an oncogenic chromosomal 
translocation, the normal non-fused ABL kinase, which is widely expressed in the body, is 
of course also inhibited by imatinib. This kinase turns out to be especially important for 
cardiomyocyte function and survival, and ABL inhibition has been identified as the root 
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cause of the cardiotoxicity of imatinib.39 Similarly, hypo-phosphataemia is probably an-
other on-target toxicity of imatinib, resulting from inhibition of PDGFR kinase activity in 
osteoclasts.40 
Various other toxicities are target-related, such as the skin toxicity of HER inhibitors.41 
Dermatological toxicities are also a feature of the multi-targeted kinase inhibitor sorafenib, 
currently approved for the treatment of metastatic clear-cell renal cell carcinoma and hepa-
tocellular carcinoma, but it is not understood if this is target-related.42 Animal studies show 
that chronic pharmacologic inhibition of HER leads to cardiac dysfunction.43 Cardiac toxicity 
–drugs causing heart muscle valve damage or potentially fatal arrhythmias– has been im-
plicated in 28% of drug withdrawals in the USA over the last 30 years. That cardiac and 
skin-related toxicities have been observed for many Tyr kinase inhibitors both in oncology 
and other indications suggests the possibility of a class effect.44 Another on-target toxicity 
is hyperglycaemia, which has often been reported as a side effect of agents targeting IGF-
IR, PI3K, AKT, and mTOR. All these kinases are important components of the insulin sig-
nalling pathway and their inhibition leads to altered hepatic glycogen metabolism and 
blockage of peripheral glucose uptake. It was shown recently, however, that drug-induced 
hyperglycaemia might be attenuated by decreasing liver glycogen storage using fasting, 
combined with a low-carbohydrate diet.45 
Approved and experimental kinase inhibitor drugs 
An overview of approved and experimental oncology kinase inhibitor drugs is given in Fig-
ure 4 and individual agents are discussed below by the kinases they act on. Details for 
compounds are summarised in Tables S2-S29. 
BCR-ABL kinase. The BCR-ABL oncogene is generated in CML by the so-called Philadel-
phia chromosome that results from a reciprocal translocation that juxtaposes the Abelson 
murine leukaemia viral oncogene homolog 1 (ABL) gene with the breakpoint cluster region 
(BCR) gene.46 Since its approval, the first ABL kinase inhibitor imatinib has been used 
successfully in the control of progression from CML chronic phase to blast crisis. Whereas 
medial survival in CML was 3 to 6 years prior to the clinical use of imatinib, a 10-year 
survival rate of 68% has been reported for patients with CML who receive imatinib after 
failure of interferon.47 
A 2nd generation of ABL inhibitors has now been approved: dasatinib and nilotinib, pre-
dominantly because many patients with CML undergo clinical relapse due to resistance to 
imatinib while these new agents are effective against most imatinib-resistant BCR-ABL 
mutants (Figure 5).48 Neither imatinib nor the 2nd-generation ABL inhibitors are selective, 
but also inhibit a range of other kinases, especially PDGFR and SCFR. In fact some of these 
agents have been used in the treatment of dermatofibroma sarcoma protuberans (DFSP) 
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and gastrointestinal stromal tumours (GIST), in which disorders PDGFR and SCFR, respec-
tively, are implicated.49 
Bosutinib is a 3rd generation ABL inhibitor. Like the 2nd-generation inhibitors, it is also 
active against the majority of imatinib-resistant BCR-ABL mutants, but it is a much more 
selective inhibitor, with only SRC kinases as significant additional targets.50 The other ap-
proved 3rd-generation inhibitor, ponatinib, on the other hand, is a multi-targeted kinase 
inhibitor, but it is the only approved ABL inhibitor that has activity against the imatinib-
resistant T315I gatekeeper BCR-ABL mutant kinase (Figure 5).51 Another BCR-ABL inhibi-
tor, radotinib (structurally closely related to imatinib), was approved in South Korea in 
2012. 
Although there are currently six approved ABL inhibitors used successfully for the treat-
ment of CML, there are at least another two ABL inhibitors at various stages of clinical 
development, including flumatinib (another compound closely related to imatinib) and ABL 
001, an allosteric (type IV) inhibitor that targets the myristoyl-binding site in the SH1 
catalytic kinase domain (Table S2). 
SRC kinases. A number of ABL kinase inhibitors approved in CML, such as dasatinib, ni-
lotinib, bosutinib, and ponatinib also inhibit the closely related SRC kinases. SRC family 
kinases are cytosolic Tyr kinases that have a multitude of functions in cellular signal trans-
duction, whose activated forms are aberrantly expressed in many solid tumours, especially 
metastatic cancers.52 This has led to clinical evaluation of such dual ABL and SRC agents, 
including saracatinib and AZD 0424 (closely related compounds that share the (6-chloro-
2H-[1,3]dioxolo[4,5-b]pyridin-7-yl)aminoquinazolin-7-yl substructure), in advanced solid 
tumours such as NSCLC, as well as in lymphomas.53 Saracatinib is also currently being 
evaluated in Alzheimer’s disease as an inhibitor of the SRC family kinase FYN, which is 
implicated in the pathogenesis of this disease.54 The most SRC-selective experimental ki-
nase inhibitor drug (Table S3) appears to be a compound known as KX 01, which is a type-
III kinase inhibitor, i.e. a peptidomimetic of SRC kinase substrate peptides (Figure 6). 
To date, therapeutic success in clinical trials of SRC kinase inhibitors has been limited and 
it has been postulated that a paradigm shift is required in clinical trial design for such 
agents in terms of patient selection, biomarker development, and rational design of com-
binatorial regimens with SRC inhibitors.55 However, recent insights suggest that highly 
selective SRC kinase inhibitors may possess significant advantages over dual ABL/SRC in-
hibitors, since tumour suppressor signalling through ABL appears to occur at least in some 
cancers.56 Inhibitors that are highly selective for SRC over ABL have recently been re-
ported, and the clinical development of such compounds may overcome this issue, as well 
as the cardiotoxicity associated with ABL inhibition.57 
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Epidermal growth factor receptor kinases. The EGFR Tyr kinase family consists of four 
transmembrane receptors, HER1–4, and signalling through this receptor family is im-
portant for many cell functions and for cell survival. At least HER1–3 are involved in tu-
mourigenesis, and hetero-dimerisation of these receptors plays an important role in their 
function.58 Inhibitors of the EGFR Tyr kinase family have been studied mostly in breast 
cancers and NSCLCs driven by HER2 and HER1, respectively. As a consequence, activating 
mutations in e.g. EGFR (such as exon 19 in-frame deletions and L858R point mutations) 
serve not only as the rationale for the use of EGFR Tyr kinase inhibitors, but also as bi-
omarkers for patient selection.59 Of the approved EGFR inhibitors, both gefitinib and erlo-
tinib (Figure 7b) are HER1-specific and are used in NSCLCs, many of which overexpress 
HER1.60 
The trend in new EGFR Tyr kinase inhibitors is now towards pan-HER-targeted compounds, 
including the approved agent lapatinib (Figure 7d), which inhibits both HER1 and HER2 and 
is used for the treatment of advanced HER2-positive breast cancer.61 Icotinib, which is 
approved in China, is also an inhibitor of both HER1 and HER2. Although HER2 lacks an 
extracellular ligand-binding domain, it is nevertheless involved in hetero-dimerisation with 
other ligand-bound EGFR partners. Because EGFR signalling that affects cell proliferation 
and survival depends on both HER1 and HER2, inhibitors that block the catalytic activity of 
both have been sought, in the hope of enhanced clinical efficacy. However, clinical studies 
of pan-HER inhibitors have been difficult due to a narrow therapeutic margin with such 
agents, with dose-limiting on-target pan-HER toxicities such as diarrhoea and skin rash.62 
Although the HER2-specific antibody drug trastuzumab has been used successfully in 
HER2-overexpressing breast cancer for some time,63 it is perhaps surprising that more 
progress has not been achieved to date with HER2-selective small-molecule kinase inhibi-
tors. Highly HER2-selective inhibitors are in fact known (Figure 7c),64 but none seem to be 
under clinical evaluation at present.  
Both acquired and innate drug resistance appear to play an important role in limiting the 
response rates to EGFR Tyr kinase inhibitor drugs. The comparatively unique presence of 
an unpaired Cys residue in the ATP-binding pocket of the EGFR Tyr kinases has allowed 
the development of irreversible ATP-site inhibitors.65 In preclinical studies it has been 
shown that cancers that have become resistant to gefitinib and erlotinib through the sec-
ondary EGFR T790M mutation (in ca. 60% of cases) remain sensitive to 2nd-generation 
type-VI inhibitors.66 This, and the observation that such inhibitors may be less likely to 
induce drug-resistant kinase mutants, might be due to the fact that covalent inhibitors can 
still block a mutant kinase that has reduced affinity for non-covalent inhibitors, because 
with covalent binders inhibition is rate- rather than affinity-driven.67 Two such agents that 
can overcome T790M mutation, afatinib (Figure 7f) and osimertinib (Figure 7g), were re-
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cently approved in metastatic NSCLC. Afatinib is a pan-HER inhibitor that blocks the cata-
lytic activity of HER1, HER2, and HER4, as well as phosphorylation of the EGFR-trans-
signalling partner HER3,68 which is itself kinase-inactive.69 Osimertinib, on the other hand, 
is selective for T790M-mutant HER1, as well as L858R and exon-19 deletion mutant forms 
of HER1. Because osimertinib spares wild-type HER1, it may have reduced toxicity com-
pared to afatinib and other EGFR inhibitors used in NSCLC.70,71 
Apart from the six small-molecule EGFR Tyr kinase inhibitors already approved, no fewer 
than four type-VI inhibitors are currently in late-stage clinical development, including da-
comatinib and neratinib (pan-HER and T790M HER1), as well as ASP 8273 and rociletinib 
(T790M HER1-selective). At least another 16 agents, with varying selectivity profiles, are 
undergoing clinical development (Table S4). 
CSF1/PDGF receptor subfamily kinases (Table S5). The CSF1/PDGF Tyr kinase sub-
family contains a number of closely related kinases that are relevant to cancer, including 
CSF1R, VEGFR/FLT, PDGFR, and SCFR (c-Kit). Vascular endothelial growth factors (VEGFs) 
act on three main receptor Tyr kinase receptors, i.e. VEGFR1, VEGFR2, and VEGFR3, 
whereas platelet-derived growth factors (PDGFs) act on the PDGFRα and PDGFRβ recep-
tors, which contain similar Tyr kinase domains. Both VEGFRs and PDGFRs activate cellular 
proliferation and survival signalling pathways, such as the RAF–MAP–MEK–ERK and the 
PI3K–AKT pathways. These receptors are implicated in tumour angiogenesis, metastasis, 
and progression.72,73 
All currently approved (and many of the late-stage development) compounds that inhibit 
CSF1/PDGF Tyr kinases are MTKIs and contain some of the original kinase inhibitor core 
templates,74 e.g. sunitinib and nintedanib are 3-methylidene-2-oxo-1H-indoles, 
vandetanib is a 4-(anilino)quinazoline, and pazopanib is a bis(arylamino)pyrimidine. These 
agents are variously used in the treatment of advanced renal cell carcinoma (sunitinib, 
axitinib, pazopanib), gastrointestinal stromal tumours (sunitinib), advanced or metastatic 
pancreatic neuroendocrine tumours (sunitinib), advanced soft tissue sarcoma (pazopanib), 
late-stage medullary thyroid cancer (MTC; vandetanib), and progressive, radio-iodine-re-
fractory differentiated thyroid cancer (lenvatinib). Nintedanib is another approved MTKI 
with activity against CSF1/PDGF kinases. It received its first global approval not in oncology 
but for the treatment of IPF. The activity in this indication may be linked to the ability of 
nintedanib, amongst other kinases, potently to inhibit FGFR Tyr kinases, as aberrant FGFRs 
appear to contribute to the pathogenesis of IPF (see below).75 Nintedanib is also now used 
for the treatment of advanced, metastatic NSCLC in combination with docetaxel. Numerous 
additional VEGFR inhibitors with varying selectivity profiles are now being developed. E.g. 
fruquitinib and cediranib are selective pan-VEGFR/PDGFR inhibitors. 
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Although there is abundant evidence that angiogenesis inhibitors can suppress tumour 
development in preclinical models, recent findings show that pharmacological as well as 
genetic VEGFR suppression can in fact alter tumour development by increasing invasion 
and metastasis.76,77 In the clinic, the response to VEGFR inhibitors is often limited and 
followed by disease progression that is at least in part due to tumour escape as a result of 
VEGFR inhibition. For these reasons research and clinical trialling of drug combination strat-
egies that may prevent such escape mechanisms are on-going.78  
Closely related to the VEGFR Tyr kinases is FLT3, which is commonly overexpressed in 
most B-lineage leukaemias (acute lymphocytic leukaemia, ALL; acute myelogenous leu-
kaemia, AML), in subsets of T-cell ALL, and CML in blast crisis. Furthermore, FLT3 activating 
mutations are present in about a third of AML patients.79 A number of multi-targeted 
CSF1/PDGF TK inhibitors with activity against FLT3 are being developed, e.g. midostaurin, 
AKN 028, and PLX 7486. Quizartinib, a benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea 
compound, is an example of a late-stage selective type-II80 FLT3 inhibitor being trialled in 
the treatment of ALL.81 Unusually for a type-I TK inhibitor, crenolanib has high selectivity 
for FLT3, SCFR, and PDGFR kinases, including resistance-conferring kinase domain mutant 
forms.82 This finding supports the emerging notion that type-II inhibitors may not neces-
sarily be intrinsically more selective than type-I inhibitors, as has been thought in the 
past.83 
Among the CSF1/PDGF Tyr kinases is SCFR. Oncogenic signalling from mutant KIT is es-
pecially common in GIST84 and currently the standard therapy for unresectable or meta-
static GISTs is first-line imatinib, second-line sunitinib, and third-line regorafenib.85 All 
three of these agents are MTKIs that were originally developed for alternative indications, 
but more selective SCFR inhibitors are also now being developed, e.g. crenolanib and PLX 
9486. The D816V KIT activating mutation occurs in > 90% of patients with systemic mas-
tocytosis and whereas imatinib is not efficacious in this indication, dasatinib has been 
shown to be active.86 
CSF1R is a cell-surface receptor for both macrophage colony-stimulating factor-1 (CSF1) 
and interleukin-34. It plays an important role as a regulator of tissue and tumour-associ-
ated macrophages.87 Because CSF1R activation promotes tumour progression through sup-
pression of the anti-tumour immune response, as well as promotion of angiogenesis and 
metastasis, CSF1R inhibitors may be particularly useful in many cancer indications. In fact 
many MTKIs from the CSF1/PDGF class also inhibit CSF1R and this activity may contribute 
to their efficacy. However, selective CSF1R inhibitors are also now under development, 
e.g. pexidartinib and ARRY 382 (undisclosed structure). 
Fibroblast growth factor receptor kinases. The four isoforms (FGFR1-4) of this recep-
tor Tyr kinase family are structurally and functionally related to the HER family and bind 
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diverse FGF ligands. FGFR signalling appears to be implicated in the pathogenesis of sev-
eral cancers and FGFR aberrations are frequent (7.1% of cancers), especially in urothelial, 
breast, endometrial, and lung cancers. Apart from finding potential therapeutic application 
against tumours with FGFR genetic alterations, FGFR inhibitors may also be useful to over-
come resistance against HER inhibitors, as alternative signalling through the FGFR pathway 
apparently represents an important escape mechanism when HER signalling is suppressed. 
Conversely, FGFR kinase inhibitors may be able to potentiate HER inhibition.88 
Many of the approved MTKIs in the CSF1/PDGF class also inhibit FGFR kinases but more 
selective FGFR kinase inhibitors are also now under development. AZD 4547, infigratinib, 
and erdafitinib (Figure 8a) are potent and selective pan-FGFR inhibitors currently under-
going phase-II trials in a range of cancers. Another 7 FGFR kinase inhibitors (structures 
not disclosed) are currently in phase-I trials (Table S6). At least two of these are irreversi-
ble inhibitors (PRN 1371; TAS 120, refer Figure 8e), whereas another is an isoform-selec-
tive FGFR4 inhibitor (FGF 401). 
One of the mechanisms of acquired resistance to FGFR inhibition is gatekeeper mutation. 
Thus V561M mutation in FGFR1 confers significant resistance to e.g. lucitanib (Figure 8c) 
but not dovitinib (Figure 8d). Interestingly AZD 4547 retains affinity for the V561M mutant 
FGFR1 by adopting an alternative binding mode in which the flexible dimethoxyphenethyl 
group –which is in contact with the wild-type V561 gatekeeper– is able to bend away from 
the larger M561 gatekeeper in the mutant kinase.89 
Hepatocyte growth factor receptor kinase (HGFR or MET). The MET Tyr kinase is a 
cell-surface receptor for hepatocyte growth factor, whose downstream signalling pathways 
are important for invasive growth in terms of motility, proliferation, and protection from 
apoptosis. These processes are important in embryonic development and tissue morpho-
genesis but often become reactivated in cancer, especially in tumour metastasis. Consti-
tutive MET activation is a feature of many cancers,32 including NSCL carcinomas with ac-
quired resistance to EGFR inhibitors.90 MET amplification can be a primary or secondary 
transformation event and e.g. in some patients with colorectal carcinomas, MET amplifica-
tion has been observed not in primary tumours, but in liver metastases.91 
The first MET Tyr kinase inhibitor to be approved for the treatment of patients with pro-
gressive metastatic MTC is cabozantinib, a MTKI with MET and VEGFR2 as its main tar-
gets.92 A range of functionally different (Figure 9) selective and MTKI MET inhibitors are 
currently under clinical evaluation in a number of cancers, including NSCLC resistant to 
EGFR inhibitors.93 The most advanced of these is tivantinib, a highly selective MET inhibitor. 
Second-generation inhibitors that are active against mutant forms of MET, such as tepo-
tinib, are also being developed (Table S7). 
 16 
Anaplastic lymphoma kinase (Table S8). ALK is a receptor Tyr kinase in the insulin 
receptor family and ALK rearrangement is second only to HER mutation as an oncogene 
addiction in NSCLC. Modification of ALK is present in only a small proportion of NSCLC 
patients but specific targeting of this population for treatment with ALK inhibitors is par-
ticularly effective.94 The first ALK inhibitor approval in NSCLC was crizotinib, a MTKI origi-
nally discovered and developed as a MET inhibitor and now prescribed successfully as first- 
or second-line therapy in ALK-positive NSCLC. ALK rearrangements also occur in > 50% 
of anaplastic large cell lymphomas (ALCLs) and crizotinib has been shown to have clinical 
activity in advanced chemoresistant ALCL.95 
The development of acquired resistance is the main reason why patients with ALK-positive 
NSCLC eventually relapse on crizotinib. Secondary resistance mutations in the ATP-binding 
site have been identified96 and one of the main drivers for the development of second-
generation ALK inhibitors has been to overcome crizotinib resistance.97 Ceritinib was ap-
proved later and is a more potent ALK inhibitor that overcomes the most common second-
ary mutation to crizotinib (gatekeeper L1196M), as does the recently approved selective 
ALK inhibitor alectinib. 
These second-generation ALK inhibitors also show activity against brain metastases, which 
is important, as almost half of ALK-positive NSCLC patients on crizotinib exhibit such me-
tastases, even when systemic disease is under control.98 Three more third-generation ALK 
inhibitors are currently undergoing clinical evaluation: brigatinib, belizatinib, and lorlatinib. 
At least the latter compound was designed specifically to have high CNS penetrance (Figure 
10).99 
IGF1R and IR. The insulin-like growth factor 1 (IGF1) signalling pathway regulates many 
aspects of the proliferation, differentiation, and growth of normal cells. However, its re-
ceptor, IGF1R, as well as its ligands and adaptor proteins, are highly expressed in many 
malignancies. Furthermore, the IGF1 pathway is also implicated in carcinogenesis and can-
cer risk. IGF1R activates the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways, both of which 
are associated with cancer cell proliferation and survival. For these reasons IGF1R inhibi-
tors have been developed, especially in NSCLC.100 The first generation of IGF1R inhibitors 
that have been tested in clinical trials are humanised monoclonal antibodies that block 
ligand binding to IGF1R. Although early results were promising, later studies using combi-
nations with chemotherapy or EGFR inhibitors in NSCLC have been disappointing.101,102 
Currently the only clinical small-molecule IGF1R inhibitor targeted at the Tyr kinase activity 
of this receptor is the phenylquinoline compound linsitinib, a dual IGF1R and insulin recep-
tor (IR) inhibitor (Table S29). 
Tropomyosin receptor kinase (Table S9). TRK was originally identified as an oncogene 
product that arises as a result of mutations and rearrangements of the NTRK genes and 
has been detected in various tumours, especially in the colon, the lung, and the thyroid 
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gland.103 The three isoforms of wild-type TRK are expressed predominantly in neurons, 
however, where their activation by neurotrophins plays important roles in cell develop-
ment, maintenance, and function. It is now clear that TRKs also regulate processes in non-
neuronal cells. Furthermore, activation of cell survival pathways through TRKs contributes 
to tumourigenesis and resistance to cytotoxic chemotherapy not only in neuroblastoma, 
but also in many other cancers.104 The TRKs belong to the same insulin receptor Tyr kinase 
subfamily as ALK and ROS, and entrectinib, a pan-TRK inhibitor with additional potent ALK 
and ROS inhibitory potency, is currently undergoing phase-II trials in colorectal carcinoma 
and NSCLC.105 Another agent at a similar stage of development is LOXO 101, a selective 
pan-TRK inhibitor. Entrectinib and LOXO 101 are structurally related, the former contains 
an indazole, the latter a pyrazolo[1,5-a]pyrimidine core, both compounds containing a 
meta-difluorophenyl substituent. 
AXL belongs to the TYRO3, AXL, and MERTK (TAM) family of receptor Tyr kinases and 
although it does not appear to be a strong oncogenic driver, it is overexpressed in many 
tumours and overexpression correlates with poor prognosis. Aberrant TAM signalling in 
cancer suggests that AXL inhibitors may confer anti-tumour immunity and tumour cell 
survival, as well as enhance chemosensitivity and suppress metastases.106 It is somewhat 
difficult to decide which development compounds should be designated as AXL inhibitors, 
since several MTKIs, including approved agents such as cabozantinib, bosutinib, crizotinib, 
and sunitinib, are also potent AXL inhibitors.107 One of the most potent AXL inhibitors (sub-
nM IC50) is the pyrazinecarboxamide gilteritinib, which also potently inhibits FLT3 and 
ALK.108 The first selective (at least in terms of cell-based kinase inhibition activity) AXL 
inhibitor to enter the clinic is BGB 324, a substituted triazole-3,5-diamine that contains two 
instances of the unusual tetrahydrobenzannulene substructure (Table S10). 
RET (REarranged during Transfection) is a receptor Tyr kinase whose activity supports cell 
survival and proliferation, as well as cell migration, differentiation, and chemotaxis. Acti-
vating mutations in RET (C634W and M918T) and a number of different gene translocations 
leading to oncogenic fusions involving RET occur in various cancers, particularly in MTC 
and NSCLC.109 RET is closely related to other receptor Tyr kinases, especially VEGFR, and 
many MTKIs possess RET-inhibitory activity (refer Tables S5, S7, S9). As we have seen, 
vandetanib, lenvatinib, and cabozantinib are approved for use in MTC and the activity of 
these agents in thyroid cancers –as well as in some lung cancers– is probably due to a 
large extent because they inhibit RET.110-113 However, the efficacy of MTKIs, especially 
those that also block VEGFR activity, is limited by toxicities114 and selective RET inhibitors 
are highly desirable for the treatment of cancers that are driven by RET activation. Alt-
hough research aimed at the discovery of such agents is under way,115,116 there do not 
appear to be any RET-specific kinase inhibitors under clinical evaluation at present. 
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Transforming growth factor-β receptor. A range of cellular responses, including pro-
liferation, differentiation, motility, and survival, are elicited upon activation by the TGF-β 
cytokines of the three TGFR isoforms through receptor hetero-dimerisation. However, in 
normal cells TGF-β actually functions as a tumour suppressor but TGF-β signalling is high-
jacked by cells during tumour development and is particularly important during the epi-
thelial–mesenchymal transition.117 TGFRs contain Ser/Thr kinase domains and signal trans-
duction occurs through TGFR heterodimer-mediated phosphorylation of cellular proteins 
such as SMADs, which activate the TGF-β signalling pathway.118 Drugs, including antisense 
oligonucleotides, antibodies, and small molecules targeting this pathway have been under 
development in both neoplastic and non-neoplastic indications, especially in fibrosis.119 
Two TGFR1 kinase inhibitors are currently being developed in oncology, galunisertib and 
TEW 7197, both of which contain the 2-methyl-6-(4H,5H,6H-pyrrolo[1,2-b]pyrazol-2-yl)pyr-
idine substructure (Table S11). 
Janus kinases. The JAK family includes the 3 cytoplasmic Tyr kinases JAK1, JAK2, and 
JAK3, as well as the non-receptor Tyr kinase TYK2. These kinases transmit signalling from 
a number of cytokines and growth factors important in haematopoiesis and cellular immune 
functions. Whereas JAK3, which is critical to signal transduction via common γ-chains of 
interleukin receptors, is pursued primarily as a drug target in inflammation, especially JAK2 
is also an oncology drug target. The interest in JAK2 inhibitors stems from the discovery 
that many myeloproliferative neoplasms display an activating mutation (V617F) in the 
JAK2 gene.120 
Ruxolitinib, a JAK1/2-selective compound,121 is the first JAK inhibitor in oncology, approved 
for the treatment of myelofibrosis. A recent survey of the clinical use of this agent con-
cluded that ruxolitinib, currently the only approved therapy for myelofibrosis, is associated 
with a survival benefit and has changed the treatment landscape for this disease.122 Nev-
ertheless, clinical responses have been attenuated and the original hope of curative effects 
with JAK2 inhibition similar to those seen with imatinib in CML, has not been fulfilled. It 
has recently been suggested that this may be due to an intrinsic resistance to JAK2 inhibi-
tion in myelofibrosis.123 
A number of other (structurally diverse) compounds (Table S12), including pacritinib 
(JAK2/FLT3-selective), momelotinib (JAK1-3-selective), are also currently undergoing clin-
ical development in myeloproliferative neoplasms.124 It is not as yet clear how these agents 
will be differentiated from ruxolitinib and if they will have to be compared to ruxolitinib in 
randomised studies for the purposes of approval.122 
Bruton tyrosine kinase. BTK is a non-receptor kinase in the B-cell antigen receptor (BCR) 
signalling cascade that mediates B-cell activation, proliferation, migration, and survival. In 
B-cell non-Hodgkin’s lymphomas (NHL) constitutive BCR activation through BTK supports 
cell proliferation and survival, rendering BTK a relevant pharmacological target in NHL. 
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This is especially attractive in terms of specificity, since the phenotype of loss-of-function 
BTK, as occurs in the human disease X-linked agammaglobulinaemia, is restricted to B-
cells.125 
The first potent and selective type-VI inhibitors of BTK were reported in 2007 and it took 
only 6 years before the first inhibitor of this type, ibrutinib, obtained initial global regulatory 
approval in the treatment of mantle cell lymphoma. The first BTK inhibitors of any kind 
were actually reported already in 1999: terreic acid (a quinone epoxide)126 and leflunomide 
metabolite analogues (2-cyano-3-hydroxybut-2-enamides).127 Since these compounds 
possess highly electrophilic functions, it is likely that they are also type-VI inhibitors that 
react covalently with the thiol of C481, an unpaired Cys residue in the ATP-binding site of 
BTK (corresponding to C773 in HER kinases), although this was not apparently realised at 
the time of their discovery. Interestingly, terreic acid was originally studied in in the con-
text of mast cell activation and it was realised that BTK inhibitors may find therapeutic 
application in immunology and inflammation, whereas leflunomide metabolite analogues 
were reported as anti-leukaemic drug leads. Ibrutinib, too, was discovered in a rheumatoid 
arthritis drug discovery programme,128 and was later repositioned in B-cell malignancies.129 
Apart from ibrutinib (a pyrazolo[3,4-d]pyrimidine) there are currently five additional BTK 
inhibitors under clinical development in cancer (Table S13). Of these the chemical struc-
tures of two are in the public domain and both are structurally closely related to ibutinib. 
Acalabrutinib is an imidazo[1,5-a]pyrazine derivative with a reactive but-2-enoyl function, 
whereas GS 4059 is a purin-8-one derivative with –like ibrutinib– an acryloyl electrophile. 
Focal adhesion kinase. FAK1 is a cytoplasmic non-receptor Tyr kinase that transmits cell 
motility, survival, and proliferation signals from integrin-mediated cell extracellular matrix 
attachment and growth factor receptors. Because metastatic propensity and poor clinical 
outcomes of many cancers are correlated with enhanced FAK1 expression and activity, 
FAK1 is a promising target for cancer therapy.130 
A number of FAK1 inhibitors have been under clinical investigation in the past,131 but cur-
rently only three remain active (Table S14). GSK 2256098 and VS 4718 are selective FAK1 
inhibitors, whereas defactinib is a dual FAK1 and FAK2 inhibitor. Such dual selectivity is 
believed to be potentially beneficial due to functional overlap and redundancy of these two 
closely related kinases.132 All three compounds are structurally related ATP-competitive 
(presumably type-I) inhibitors, but allosteric FAK1 inhibitors have also been reported,133 
although these have not yet reached clinical evaluation. 
Spleen tyrosine kinase. SYK is a cytoplasmic non-receptor Tyr kinase expressed pre-
dominantly in haematopoietic cells. Phosphorylation of cytoplasmic immunoreceptor tyro-
sine-based activation motifs (ITAMs) leads to recruitment of SYK, which propagates sig-
nalling by activation of downstream pathways, including PI3K, MAPK, and BTK.134 Because 
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SYK mediates cellular responses to antigens and antigen-immunoglobulin complexes it is 
especially relevant as a drug target to suppress the consequences of acute and chronic 
inflammation.134 However, SYK, together with BTK, is also involved in dysregulation of BCR 
signalling in haematological malignancies such as diffuse large B-cell lymphoma (DLBCL), 
follicular lymphoma, and chronic lymphocytic leukaemia (CLL).135 
A number of SYK inhibitors have been evaluated clinically, mainly for the treatment of 
immune disorders, but were found to exhibit dose-limiting toxicities attributed predomi-
nantly to lack of sufficient selectivity for SYK.136 The first of these was fostamatinib (a 
methylene phosphate oral prodrug of a poorly soluble dianilinopyrimidine compound), 
which failed in phase-III trials in rheumatoid arthritis and has also been trialled in B- and 
T-cell lymphoma, but apparently has not progressed.137 Second-generation SYK inhibitors 
with improved kinome selectivity profiles have now been developed and entered the clinic 
(Table S15). The most advanced of these is entospletinib, a highly SYK-selective oral di-
substituted imidazo[1,2-a]pyrazine compound, currently in phase-II studies in both in-
flammation and cancer (haematological malignancies). Cerdulatinib is a dual JAK and SYK 
inhibitor (Table S12) that has activity in autoimmunity and B-cell cancers like other SYK 
inhibitors.138 
PI3K pathway kinases (Table S16). The PI3K pathway regulates protein synthesis, cell 
growth, and cell proliferation in response to nutrient availability and mitogenic growth fac-
tors. Activation of this pathway has long been associated with malignant transformation 
and anti-apoptotic signalling.139 Amplification or mutation of many receptor Tyr kinases, 
mutation of downstream signalling components, including PI3K itself, loss or mutation of 
the PTEN tumour suppressor protein, as well as mutation and amplification of AKT, can 
lead to pro-survival signalling through the PI3K–AKT–mTOR–eIF4E pathway in cancer cells. 
At least four kinases in this pathway, PI3K itself (i.e. the class-I PI3K isoforms α–δ), AKT, 
its activating kinase PDK1, and mTOR, are being actively pursued as oncology drug targets. 
The first generation mTOR inhibitors are derived from the macrolide rapamycin (sirolimus), 
a natural product from a fungus indigenous to the Easter Island (Rapa Nui). Studies based 
on the observation that rapamycin inhibited the proliferation of T-cells led to the discovery 
of the mTOR (mechanistic or mammalian target of rapamycin) genes and the development 
of sirolimus as a targeted drug. Although the anticancer activities of rapamycin had been 
known for a long time, sirolimus was first developed as an immunosuppressive agent. 
However, a rapalogue (rapamycin analogue), temsirolimus, was approved for the use in 
advanced renal cell carcinoma (RCC). Objective responses of kidney cancer patients to 
rapalogues had been observed already in phase-I studies140 and the demonstration that 
loss of the von Hippel-Lindau tumour suppressor gene (VHL) sensitises kidney cancer cells 
to mTOR inhibitors subsequently enabled biomarker-driven development of temsirolimus 
in RCC.141 Another rapalogue, everolimus, was approved later for the same indication . 
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mTOR participates in at least two functionally distinct multiprotein complexes termed 
mTORC1/RAPTOR and mTORC2/RICTOR. Rapalogues, which block mTOR activity indirectly 
in complex with the immunophilin receptor known as FK506-binding protein-12 (FKBP12), 
specifically inhibit mTORC1.142 It was reported recently that the rapalogue everolimus can 
also act as a MET inhibitor (refer section on hepatocyte growth factor receptor kinase), 
since MET –like mTOR– also requires FKBP12 binding for full activity.143 Because of the 
presence of mTORC1-dependent negative feedback loops via the mTOR phosphorylation 
substrate ribosomal protein S6 kinase β-1 (S6K1) leading to upregulation of PI3K and RAS 
activities, inhibition of mTORC1 can lead to activation of AKT- and MAPK-dependent sur-
vival pathways.144 For this reason, selective ATP-antagonist mTOR inhibitors, which block 
both mTOR complexes, were developed and are also now entering clinical trials. Clinical 
compounds belonging to this group include vistusertib, sapanisertib, and CC 223. 
Unsurprisingly considering the similarity of mTOR and PI3K, the majority of ATP-antagonist 
mTOR inhibitors turned out to inhibit PI3K as well, or they were designed to possess dual 
specificity. Again several compounds of this type are being developed, e.g. the dual pan-
class I PI3K and mTOR kinase inhibitors voxtalisib, LY 3023414, PQR 309, gedatolisib, and 
VS 5584. 
Inhibitors that do not modulate mTOR at all but inhibit various combinations of class-I PI3K 
isoforms are also now being pursued. This appears to be a valid approach as all four func-
tionally non-redundant isoforms can generate the signalling molecule phosphatidylinositol-
3,4,5-trisphosphate (PIP3), which recruits AKT to the cell membrane, and because all are 
oncogenic in model systems.145 Furthermore, all four isoforms are frequently genetically 
altered in a variety of cancers.146 At present it remains unclear what PI3K/mTOR inhibition 
selectivity (Figure 11) will be therapeutically optimal. It is likely that the preferred class-I 
PI3K target will depend on the cellular context.147 The main driver for seeking isoform-
selective PI3K inhibitors is probably because broad selectivity may limit the therapeutic 
margin of an mTOR/PI3K inhibitor, due to the important role of the PI3K pathways in 
normal cells. Currently there are several pan-class-I PI3K inhibitors undergoing clinical 
trials, including buparlisip, copanlisip, pictilisib, ZSTK 474, and SF 1126, the latter being a 
vascularly targeted prodrug. 
That PI3Kδ is only expressed in haematopoietic cells provides the therapeutic rationale for 
the use of the PI3Kδ-selective compounds in haematological cancers148 and this concept 
has now led to the first approval of a PI3Kδ-selective inhibitor, idelalisib as monotherapy 
for follicular and small lymphocytic lymphoma. Another compound, duvelisib, with a similar 
selectivity profile (10- to 40-fold selectivity over PI3Kγ and higher over other PI3Ks) is in 
late-stage development. Other clinical compounds with more or less pronounced PI3Kδ 
selectivity include AMG 319, HMPL 689, INCB 050465, and CDZ 173. A recent study showed 
that PI3Kδ (and PI3Kγ) is important for T-cell-mediated immune tolerance to cancer and 
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PI3Kδ inhibitors may therefore find therapeutic applications not just in blood cancers but 
perhaps much more widely.149 
Apart from PI3Kδ-selective inhibitors, a growing number of experimental PI3K inhibitor 
drugs with a range of PI3K isoform selectivity profiles are being investigated. The interest 
in PI3Kα-selective agents stems predominantly from the observation that the gene encod-
ing this isoform is mutated particularly frequently in certain cancers (e.g. HER2- and KRAS-
driven tumours).150 The most advanced PI3Kα-selective compounds are alpelisib and tale-
lisib; others include MLN 1117 and AZD 8835. Because PI3Kα specifically regulates glucose 
haemostasis, this must be carefully managed with PI3Kα-selective inhibitors in the clinical 
setting.151 Dependence on PI3Kβ has been observed in certain PTEN-deficient tumours and 
the first PI3Kβ-selective agent, GSK 2636771 is now being trialled in this setting. Other 
PI3Kβ-selective clinical compounds include AZD 8186 and KA 2237. 
Because of the importance of the PI3K pathway to cancer cell survival, it was originally 
thought that PI3K inhibitors might have anticancer efficacy in monotherapy, but with the 
clinical experience amassed so far with over 20 different PI3K/mTOR inhibitors, it is in-
creasingly becoming clear that this is unlikely to be the case. Like most kinase inhibitors, 
PI3K inhibitors will probably work best in combination with other anticancer drugs.152 
AKT (also known as PKB) is a Ser/Thr kinase that acts downstream of PI3K and is activated 
by recruitment to the cell membrane by interaction with PIP3 through its PH (pleckstrin 
homology) domain. Once activated, AKT mediates downstream responses by phosphory-
lation of multiple proteins. The lipid phosphatase PTEN, which is frequently inactivated in 
human tumours, negatively regulates AKT by dephosphorylation of PIP3, whereas AKT is 
amplified or overexpressed in many tumours.153 
Until recently the clinically most advanced AKT inhibitor was the alkylphospholipid perifo-
sine. It is not a direct kinase inhibitor but interferes with membrane localisation of AKT.154 
Phase-II clinical trials of perifosine as a single agent in several tumour types failed to show 
objective responses.153 Although promising activity in patients with RCC, who have failed 
prior Tyr kinase inhibitor therapy, was reported,155 perifosine does not appear to be under 
development any longer. Several type-I pan-AKT inhibitors, including AZD 5363, ipa-
tasertib (Figure 12a,c), LY 2780301, and afuresertib are now in phase-II clinical studies 
and several more compounds are in early stage trials (Table S17), including the allosteric 
(type-III) AKT inhibitor MK 2206 (Figure 12a). This compound binds to an AKT site formed 
only in the presence of the PH domain and binding of the inhibitor promotes the formation 
of an inactive kinase conformation.156 MK 2206 is similar to compound VIII of ref.157, whose 
experimental binding mode is known (Figure 12b,c). ARQ 092 and BAY 1125976 are also 
allosteric AKT inhibitors. The structure of the latter compound has not yet been disclosed 
but the compound series that encompasses ARQ 092 is structurally related to compound 
VIII and MK 2206.158  
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PDK1 plays an important role in the PI3K–AKT pathway. It activates AKT, as well as a 
number of other related AGC kinases, thus controlling several signalling pathways im-
portant in proliferation, apoptosis, and angiogenesis. Like PI3K, PDK1 is upregulated in 
more than half of all tumours due to constitutive growth factor receptor activation and 
PTEN mutations. As expected, transgenic mice expressing low levels of PDK1 are protected 
from tumourigenesis that normally results from loss of PTEN. The search for potent and 
selective PDK1 inhibitors has been pursued for some time but as with many other kinases, 
achieving selectivity in inhibitors has proven challenging.159 Nevertheless, the first PDK1 
inhibitor, AR 12, recently entered clinical trials (Table S29). This compound was designed 
from celecoxib, a cyclooxygenase-2 (COX2) inhibitor, following the assignation of tumour-
preventive properties of celecoxib to PDK inhibition. However, the activity and selectivity 
with which AR 12 inhibits PDK1 is actually uncertain.159 
Protein kinase C. PKC overexpression has been linked to several types of cancer, with 
the PKCβ isoform believed to be involved in VEGF-induced tumour development and angi-
ogenesis and in the apoptosis-regulating PI3K–AKT pathway. The macrocyclic bisindol-
ylmaleimide enzastaurin selectively inhibits PKCβ at low concentrations, and also inhibits 
other PKC isozymes at higher concentrations that are reached or surpassed in clinical tri-
als.160 Anti-tumour activity of enzastaurin has been primarily attributed to the inhibition of 
AKT and its downstream targets, but its precise mechanism of action is not well under-
stood.161 Both PKC and AKT are activated by PDK, and several PKC isozymes can also 
directly phosphorylate AKT at Ser473, which is essential for AKT activity. It was recently 
reported that a phase-III clinical trial of enzastaurin in monotherapy in diffuse large B-cell 
lymphoma failed to show a statistically significant increase compared to placebo in disease-
free survival in patients at high risk of relapse following rituximab-based chemotherapy,162 
and apparently development of this compound has been discontinued. 
Enzastaurin is not the first staurosporin derivative to undergo clinical development, e.g. 
UCN-01 (7-hydroxystaurosporin) and midostaurin, which also inhibit PKC but have been 
developed as MTKIs (main targets are CHK1 and PDK1 for UCN-01, and FLT3 and other 
CSF-1/PDGF receptor subfamily kinases for midostaurin).163,164 Other staurosporine deriv-
atives are being developed in non-oncology indications.165 The only PKC inhibitor that re-
mains under clinical study appears to be LXS 196, an oral compound whose structure or 
properties have not yet been disclosed (Table S29). 
Choline kinase-α. CK is a lipid kinase that phosphorylates free choline to give phospho-
choline, enabling the formation of phosphatidylcholine, the main phospholipid in mamma-
lian cell membranes, through the Kennedy pathway. Many tumours display altered lipid 
metabolism during development and as a consequence of chemotherapy CK is up-regu-
lated in many tumours and is associated with various malignant phenotypes.166 Further-
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more, CK was recently reported as an androgen receptor chaperone and potentially valu-
able drug target in prostate cancer.167,168 TCD 717 is the first CK inhibitor to have recently 
entered clinical trials in solid tumours (Table S29). It inhibits CK by virtue of competing 
with the substrate choline; its structure has not been disclosed but is related to hemicho-
linium-3 ((2S,2'S)-2,2'-biphenyl-4,4'-diylbis(2-hydroxy-4,4-dimethylmorpholin-4-ium), a 
choline re-uptake inhibitor.169 
Casein kinase II is a constitutively active hetero-tetrameric Ser/Thr kinase that sustains 
many cellular signalling pathways. Although CK II function is not apparently altered in 
cancer cells by mutation, it is nevertheless overexpressed in many different cancers.170 
Tumour cells often exhibit CK II-driven non-oncogene addiction171 and it has been shown 
that ablation of CK II through antisense oligonucleotides has profound anti-proliferative 
and pro-apoptotic effects in a rodent xenograft model.172 A number of small-molecule CK 
II inhibitors with anticancer activity have been reported and the first such compound, sil-
mitasertib, an CK II-selective ATP-competitive benzo[c][2,6]naphthyridine-8-carboxylic 
acid compound, has recently entered clinical evaluation (Table S29).173 
MELK is an AMPK family kinase with several cellular functions related to survival and pro-
liferation and it is overexpressed in many tumours. These functions appear to be especially 
important in cancer stem cells, i.e. undifferentiated cancer cells. The first clinical MELK 
inhibitor is OTS 167, a disubstituted (naphthyridin-3-yl)ethanone compound, whose bind-
ing mode was reported recently.174 Another clinical compound, the (indol-3-ylidene)me-
thyl)pyrrole amcasertib, also targets (undisclosed) cancer stem cell pathway kinases (Ta-
ble S29). 
PIM. The proviral insertion in murine (PIM) lymphoma family of Ser/Thr kinases (PIM1-3) 
is expressed predominantly in haematopoietic cells and signals downstream from ABL, 
JAK2, and FLT3. PIM kinases contribute to the regulation of the cell cycle, apoptosis, and 
the proliferation and migration of cells. All three isoforms have oncogenic potential and are 
aberrantly expressed in various tumours.175 Although mouse knock-out of any of the three 
PIM kinases results in mild phenotypes, deficient PIM1 signalling is associated with cardiac 
function and PIM triple knock-out mice develop heart failure by 6 months. These observa-
tions may be relevant to the withdrawal of the first-in-class clinical PIM inhibitor SGI 1776 
due to cardiotoxicity.176 Despite this observation it would appear that both PIM inhibitors 
currently undergoing clinical development, i.e. INCB 053914 and PIM 447 (Table S18) are 
pan-selective PIM inhibitors. PIM kinases are somewhat unusual insofar as they recognise 
ATP, as well as most inhibitors, in a manner that does not involve the typical H-boding 
interactions between the kinase hinge region and the ligand, due to the presence of two 
Pro residues in the PIM hinge, which imparts an atypical conformation to this region.177 
This unusual recognition mode may explain the high kinome-wide selectivity of compounds 
such as PIM 447. 
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Mitogen-activated protein kinase pathway kinases. The RAS–RAF–MEK–ERK MAPK 
pathway is one of the main signalling pathways that cancer cells use for the purposes of 
proliferative and survival advantages. Activation of the MAPK pathway, through activating 
mutations in either NRAS or BRAF, is particularly common in melanoma.178 Below we shall 
discuss clinical RAF (Table S19) and MEK inhibitors (Table S20), which have recently been 
joined by the first ERK inhibitors (Table S21). 
Currently there are two RAF kinase inhibitors approved for the treatment of unresectable 
or metastatic melanoma with BRAF V600E mutation, vemurafenib and dabrafenib. Both 
compounds display selectivity for V600E BRAF over other kinases, and to a lesser extent 
over wild-type RAF kinase isoforms.179,180 With these compounds, inhibition of the MAPK 
pathway is specific to tumour cells with mutant BRAF and this is likely due to their selec-
tivity. In the majority of melanoma patients treated with vemurafenib or dabrafenib sig-
nificant tumour regression and progression-free survival have been observed, a result that 
compares favourably with previously available therapies for metastatic melanoma.178 
Neither agent is indicated for the treatment of patients with wild-type BRAF melanoma due 
to the potential risk of tumour promotion, and both were approved concurrently with as-
says for the detection of BRAF V600E mutations. This contra-indication is due to paradox-
ical activation of the MAPK pathway by RAF inhibitors in cells with wild-type BRAF. MAPK 
pathway activation occurs as a result of RAS-dependent MEK phosphorylation by homo- 
and hetero-dimerised RAF isoforms. In mutant BRAF melanoma cells, in which MEK acti-
vation is driven by BRAF, RAF inhibition is effective because of increased affinity of BRAF 
V600E for ATP and lack of CRAF activation. Paradoxical MAPK pathway activation in cells 
with normal BRAF, where RAS signalling occurs predominantly through CRAF, is thought 
to arise due to binding of type-I RAF inhibitors to wild-type RAF isoforms, which leads to 
their loss of auto-inhibition in a manner that is independent of kinase inhibition, enhanced 
RAF dimerisation, membrane localisation, and eventually RAS-dependent MEK activa-
tion.181,182 The same phenomenon, i.e. paradoxical MAPK pathway activation in healthy 
keratinocytes, is probably responsible for the significant cutaneous toxicities observed with 
RAF inhibitors.183 
Despite the approval of vemurafenib and dabrafenib, a whole range of additional RAF ki-
nase inhibitors are currently being developed in advanced melanoma and other solid tu-
mours (Table S19).184 The first RAF inhibitor studied in melanoma, however, was sorafenib, 
a type-II MTKI with pan-RAF activity. This compound, which also has activity against sev-
eral CSF1/PDGF receptor subfamily kinases (Table S5), was being developed –and is now 
approved in– advanced RCC at the time when the BRAF V600E mutation, which is present 
in over half of all malignant melanomas, was first discovered.185 Despite several clinical 
trials of sorafenib in melanoma, it was not possible to show significant patient benefit, 
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however. Presumably this was because at the maximum tolerated dose, defined by toxic-
ities emanating from inhibition of kinases other than RAF, there was insufficient MAPK 
pathway inhibition.178 
The first MEK inhibitor (Table S20) approval was trametinib in the treatment of patients 
with unresectable or metastatic melanoma with BRAF V600E or BRAF V600K mutation as 
detected by an FDA-approved test. This offers another treatment modality in this disease, 
although it is not as yet clear what the best treatment options with RAF and MEK inhibitors 
are.186 Nevertheless, acquired resistance to RAF inhibitors occurs frequently and through 
multiple genetic mechanisms, which suggests that simultaneous inhibition of MEK and mu-
tant RAF kinases may be a better strategy in terms of overall efficacy, prevention of MEK-
driven acquired resistance, and modulation of toxicity emanating from paradoxical MAPK-
pathway activation with RAF-inhibitor monotherapy.187 On this basis cobimetinib was re-
cently approved for the treatment of mutant BRAF melanoma in combination with vemu-
rafenib. 
The selectivity of trametinib and cobimetinib, as well as other MEK inhibitors under clinical 
development,188 including rafametinib, selumetinib, pimasertib, PD-0325901,	binimetinib, 
RG 7304, and TAK 733, is probably because these compounds target a non-conserved 
allosteric site in MEK1 and MEK2 (Figure 13). 
Although treatment of advanced melanoma with both RAF and MEK inhibitors has been 
observed to be effective initially, resistance to both inhibitor types eventually occurs.189 
The main mechanisms of acquired resistance appear to be reactivation of the MAPK path-
way in a number of ways, as well as compensatory signalling through the parallel PI3K 
pathway.178 The latter observation has led to the initiation of clinical trials in melanoma 
and other solid tumours, where RAF/MEK and PI3K inhibitors are used in combination.190 
Direct targeting of ERK1/2 in order to block signalling through the RAS–RAF–MEK–ERK 
pathway has lagged behind the upstream inhibition strategies, but may be of benefit in 
several ways.191 Thus it has been demonstrated that dual pharmacological inhibition of 
MEK and ERK can be synergistic by inhibiting the emergence of resistance and overcoming 
acquired resistance to MEK inhibitors.192 There are currently three ERK1/2 inhibitors under 
clinical evaluation (Table S21), the most advanced being ulixertinib. Both ulixertinib and 
GDC 0994 contain the N-((1S)-2-hydroxy-1-phenylethyl)formamide substructure, whereas 
the chemical structure of CC 90003 has not been disclosed. 
p38 MAPK. Several different MAPK signalling pathways are used by cells to respond to 
extracellular stimuli. Apart from the RAS–RAF–MEK–ERK we have just discussed, another 
important MAPK pathway is the p38 MAPK pathway, which mediates stress responses and 
responses to cytokines, chemokines, hormones, and growth factors. The four p38 Ser/Thr 
kinase isoforms p38α (MAPK14), p38β (MAPK11), p38δ (MAPK13), and p38γ (MAPK12) 
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can be activated in a number of ways involving both posttranslational modification and 
protein interactions, thus integrating many different signals. In turn the p38 kinases have 
numerous downstream targets and can activate different transcriptional programmes in a 
spatially and temporally controlled manner.193 
p38 MAPK is pursued mainly as a drug target in chronic inflammatory disorders, especially 
p38α, which is over-activated in inflamed tissues. Many different p38 MAPK inhibitors are 
being developed in such disorders, including rheumatoid arthritis, atherosclerosis, and 
asthma.194,195 However, p38 MAPKs also play important roles in the responses of cancer 
cells to oncogenic stress, radiation, and chemotherapy and altered expression of p38 
MAPKs is frequently observed in tumours, where they promote tumourigenesis.196 Cur-
rently two structurally related p38 MAPK inhibitors are under clinical investigation in on-
cology indications: ralimetinib and pexmetinib (Table S22). 
MNK. The Ser/Thr kinases MNK1 and MNK2 are activated through the mitogen- and stress-
activated MAP kinase pathways and they phosphorylate the eukaryotic translation initiation 
factor 4E (eIF4e). Genetic studies indicate that whereas MNK activity is required for eIF4E-
mediated oncogenic cell transformation, such activity is dispensable for normal develop-
ment.197 Until recently very few MNK inhibitors were known but selective type-I/II and 
type-VI MNK inhibitors have now been reported.198,199 The first MNK inhibitor to reach 
phase-I clinical trial is BAY 1143269 (Table S29; undisclosed structure). 
Cyclin-dependent kinases (Table S23). The CDKs comprise a large group of Ser/Thr 
kinases involved predominantly in the control of the cell cycle and the regulation of tran-
scription. Recruitment into and progression through the cell cycle are tightly regulated and 
the interphase CDKs control the first gap phase (G1; CDK4, CDK6, CDK1, CDK2) by acti-
vating E2F-responsive genes required for entry to the DNA synthesis phase (S-phase), as 
well as the second gap phase (G2; CDK1, CDK2) by activating the FoxM1 gene programme 
required for execution of mitosis. Similarly, the different phases of RNA polymerase II 
(RNAPII)-based transcription are regulated by CDKs. Here sequential phosphorylation of 
the C-terminal domain of RNAPII occurs: by CDK7 and CDK8 in transcription initiation, and 
by CDK9 in RNA elongation. Additionally, CDK activity is required (at least CDK11) for RNA 
processing (splicing).200 However, our understanding of CDK biology is still incomplete due 
to extensive functional overlap and redundancy between the many CDK–cyclin pairs, not 
only in the cell cycle and RNAPII transcription, but also between the two. 
Because cancer is characterised by uncontrolled cell division, interference with CDKs as 
key regulators of the cell cycle appears attractive as a therapeutic strategy. However, the 
complexity of CDK–cyclin biology has confounded interpretable genetic target validation of 
CDKs. As a result uncertainty exists about which CDK function(s) should be blocked to 
achieve effective and specific anticancer activity in a therapeutic setting, and this has long 
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beset the development of CDK inhibitor drugs. A large number of CDK inhibitors had been 
trialled clinically in the past – mostly with disappointing results.201 
Nevertheless, the first CDK inhibitor, palbociclib, has now been granted FDA approval for 
use in combination with letrozole (a non-steroidal aromatase inhibitor) in ER-positive, 
HER2-negative metastatic breast cancer. Palbociclib is a highly CDK4/6-selective agent 
and preclinical studies with this and several other CDK4/6-selective compounds show an-
ticancer activity in a range of models, with this activity being contingent on the presence 
of functional retinoblastoma protein (pRb; the CDK4/6 phosphorylation substrate), and 
leading to cytostatic G1 arrest. Rapidly reversible neutropenia is the main dose-limiting 
toxicity of palbociclib, as one would expect on mechanistic grounds.201 
Other CDK inhibitors that remain under clinical development include two more CDK4/6-
selective agents: ribociclib, abemaciclib, as well as number of pan-CDK-selective com-
pounds: dinaciclib, AT 7519, milciclib, roniciclib, and CYC 065. Additionally, MTKIs that 
may be classed as CDK-inhibitors are TG 02 and RGB 286638. 
The kinase inhibitor that probably has a longer clinical development history than any other 
is alvocidib (flavopiridol). This compound has been difficult to develop due to target prom-
iscuity and limitations in formulation and disposition, but marked efficacy was observed 
some time ago in CLL, and this activity was ascribed to potent CDK9 inhibition by alvocidib. 
CLL –and many other cancers– are known selectively to depend on efficient RNA synthesis 
in order to support anti-apoptotic signalling, which in turn requires CDK9 activity.202 Al-
vocidib has now re-entered clinical development, based on promising activity in AML, also 
likely due to potent CDK9 inhibition. The first selective CDK9 inhibitor, BAY 1143572, has 
also now entered clinical trials. This compound contains the unusual sulfoximine solubilis-
ing substructure.203 
Aurora kinases. ARKs are a group of mitotic Ser/Thr kinases and in humans there are 
three homologues. ARK-A regulates mitotic entry, spindle assembly, alignment of meta-
phase chromosomes, and completion of cytokinesis. ARK-B and ARK-C, on the other hand, 
are chromosomal passenger proteins predominantly involved in chromosomal bi-orienta-
tion. ARKs play important roles in the maintenance of genetic stability and their aberrant 
expression leads to genomic instability or aneuploidy. Because ARKs are overexpressed in 
many cancers, thus generating aggressive tumours, they are regarded by many as attrac-
tive targets for cancer therapy.204 
There is an on-going debate in the field about what ARK selectivity is optimal in terms of 
efficacy and on-target toxicity. Currently six ARK inhibitors (Table S24) with different se-
lectivity profiles are being trialled in a variety of solid tumours and blood cancers. Com-
pounds selective for ARK-A are alisertib and TAS 119, whereas barasertib is selective for 
ARK-B. Danusertib is a selective pan-ARK inhibitor. ENMD 2076 and ilorasertib, on the 
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other hand, are multi-targeted ARK inhibitors. An answer regarding desirable selectivity 
may therefore emerge. At this stage, however, this questions remains open. 
Whereas some therapeutic effects have been seen with most experimental ARK inhibitor 
drugs, it would appear that all of them suffer the same limitations as classical antimitotic 
agents, i.e. cytostatic or cytotoxic effects against proliferating cells only, without good 
discrimination between transformed and normal cells, which manifest clinically as neutro-
penia and other haematological toxicities. Interestingly, several ARK inhibitors have been 
found to be effective against imatinib- and 2nd-generation Tyr kinase inhibitor-resistant 
forms of the BCR-ABL kinase, especially the T315I mutant form. Some ARK inhibitors are 
now being tested clinically in patients with imatinib-resistant CML.205 
Polo-like kinases. PLK1 is one of four related Ser/Thr kinases associated with cell prolif-
eration, especially in the mitotic phase of the cell cycle. Most cancers exhibit higher PLK1 
expression than corresponding normal tissues, and PLK1 inhibition results in G2-M phase 
arrest, activation of the mitotic checkpoint, spindle dysfunction, and apoptosis in cancer 
cells. To date several PLK inhibitors have entered clinical evaluation, so far with disappoint-
ing results in terms of efficacy and with neutropenia as the most prominent toxicity.206 The 
most advanced experimental PLK inhibitor drug is volasertib, a potent and selective PLK1 
inhibitor with pronounced anti-tumour activity in preclinical models, including taxane-re-
sistant colorectal cancer. One of the possible reasons for the limited anticancer activity 
observed with this agent in humans may be its limited bioavailability in tumours compared 
to normal tissues.207 Using a genome-wide synthetic lethality screen it was shown recently 
that KRAS-driven tumours are selectively sensitive to PLK1 inhibition.208 This finding might 
be used profitably to guide patient selection in efficacy trials of experimental PLK1 inhibitor 
drugs. PLK4, which is involved in centriole duplication, has not as yet received significant 
attention as an oncology target, but a selective PLK4 inhibitor, CFI 400945, has recently 
entered clinical evaluation (Table S25). 
DNA damage response pathway kinases. The PI3K–related kinase (PIKK) family in-
cludes ATM, ATR, DNA-PK, hSMG1, mTOR (discussed above under PI3K pathway inhibi-
tors), and TRRAP, all large proteins that contain a C-terminal kinase domain closely related 
to the lipid kinase PI3K, but which function as Ser/Thr kinases, whereas CHK1 and CHK2 
are Ser/Thr kinases in the CAMK family (NIM1 subfamily). Several PIKKs, including ATM, 
ATR, and DNA-PK, as well as the CHK kinases, are implicated in DNA replication and dam-
age checkpoint pathways. 
The DNA damage response helps cells to maintain genomic stability and the two main 
signalling routes are the ATM–CHK2 pathway, which controls DNA double-strand break 
repair, and the ATR–CHK1 pathway, which responds primarily to single-stranded DNA. 
DNA-PK, on the other hand, plays a role in DNA repair by non-homologous end joining. 
ATM and ATR act on their CHK substrates, which in turn promote cell-cycle arrest to allow 
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time for repair, as well as on numerous other components involved in DNA repair, apopto-
sis, and the cell cycle. Since efficient DNA repair allows cancer cells to tolerate not only 
oncogenic replication stress, but also exogenous genotoxic stress from radio- and chemo-
therapy, the DNA response pathway may represent a promising target for cancer therapy. 
At least ATR and CHK1 inhibitors are believed to be potentially useful for monotherapy of 
certain cancers, e.g. those with p53 and other DNA damage response deficiencies, whereas 
ATM, ATR, CHKs, and DNA-PK inhibitors are all potentially valuable as radio- and chemo-
sensitising agents.209 
Although a number of CHK inhibitors had been clinically evaluated in the past,210 currently 
only the CHK1 inhibitors prexasertib and GDC 0575 remain under active development (Ta-
ble S26). The first selective ATR inhibitors to enter the clinic are VX 970, VX 803, and AZD 
6738 (Table S27). Additionally, the ATM inhibitor AZD 0156 (Table S29) and the DNA-PK 
inhibitors VX 984 and M 3814 (Table S28) are in early clinical trials. Finally the first-in-
class WEE1 inhibitor AZD 1775 (Table S29) should be mentioned here, as WEE1 is another 
kinase associated with cell cycle checkpoint control following DNA damage. 
CDC7. CDC7 is a Ser/Thr kinase that is involved in regulation of the S-phase and mitosis 
during the cell cycle. CDC7 inhibition has been reported to block DNA replication without 
activation of the S-phase checkpoint and directly to induce cellular apoptosis in trans-
formed cells but not in normal cells.211 A number of CDC7 inhibitors have been reported 
and several have undergone early clinical evaluation.212 However, at present the only CDC7 
inhibitor in the clinic is TAK 931 (Table S29; undisclosed structure). 
Medicinal chemistry 
Of the 231 (at the time of writing) clinical kinase inhibitor anticancer drugs, chemical struc-
tures for 172 are in the public domain. These molecules display structural and physico-
chemical properties as summarised and compared to those of all currently approved small-
molecule drugs in Table 1. 
In terms of physicochemical properties, it can be seen that on average oncology kinase 
inhibitors are significantly larger (by almost a third; Mr) and more lipophilic (by around two 
thirds; logP, logD) than small-molecule drugs in general, and they have much lower (pre-
dicted) intrinsic water solubility (by almost half; logS). Increased lipophilicity and lower 
solubility stem predominantly from relatively abundant aliphatic and aromatic systems 
(nAr) present in oncology kinase inhibitors. Furthermore, kinase inhibitors are compara-
tively more flexible (nRot) and contain more polar functionalities for H-bonding interactions 
(TPSA, HBA, HBD) than approved drugs in general. Structurally, kinase inhibitors on aver-
age contain more cyclic systems (nRing, nAr) but fewer chiral centres (nChir) than other 
drugs, presumably because kinase inhibitors, unlike many other drugs, are less frequently 
derived from natural products. 
 31 
Correlation of logP and logS (Figure 14) shows that most of the kinase inhibitor drugs are 
expected to be highly permeable but poorly soluble, some of them with exceptionally low 
(predicted) intrinsic aqueous solubility. With very few exceptions kinase inhibitor drugs are 
being developed as immediate release products for administration by the oral route and 
while the physicochemical properties in Table 1 are consistent with oral bioavailabil-
ity,213,214 average Mr and logS suggest an average thermodynamic aqueous solubility of 
about 2 µg/mL (75 µg/mL for all approved drugs), which is only expected to be consistent 
with very low clinical doses, and provided permeability is high.215 For many oncology kinase 
inhibitors absorption is likely to be variable and in vivo drug dissolution rate-limiting. It 
can therefore be expected that many kinase inhibitor drugs will be challenging to develop 
from a formulation viewpoint. 
As can be seen from Figure 15, both the maximum and average structural dissimilarity 
amongst oncology kinase inhibitors is significantly lower than that of all approved drugs, 
indicating that many kinase inhibitors, which generally target the conserved ATP-binding 
site, are pharmacophorically related. As expected, dissimilarity of compounds that are tar-
geted to subgroups or individual kinases is diminished compared to that of all experimental 
kinase inhibitors. The groups of kinase inhibitors with the highest and lowest average 
structural dissimilarity are the PI3K and CSF-1/PDGF inhibitors on the one hand, and the 
BCR-ABL inhibitors on the other. 
Another way of looking at structural similarity of oncology kinase inhibitor drugs is to as-
sess the frequency at which common substructures occur in these compounds (Figure 16). 
This shows that by far the most common substructure is the formanilide group (31 in-
stances). This is probably not a distinguishing structural feature of kinase inhibitors, as 
this group occurs frequently in many different drug classes. The next most frequent sub-
structure, however, is the quinazoline group (14 instances), a commonly used kinase in-
hibitor core, which occurs in several approved drugs and many experimental agents, es-
pecially in EGFR inhibitors. Other substructures that occur more than three times in the 
172 oncology kinase inhibitors are the ethoxybenzene (11), 2-anilinopyrimidine (10), ben-
zamide (8), indole (8), benzimidazole (5), chromene (4), 4-(pyrimidinyl-4-yl)morpholine 
(4), (3-fluorophenyl)methanamine (4), 2-phenylethylamine (4), and N,4-dimethylpyrim-
idin-2-amine (4). Again some of these substructures are not specific to kinase inhibitors 
but it is notable that 3 of these substructures contain the pyrimidine heterocycle. Of the 
substructures that occur twice or three times a number of N-containing bicyclic heterocy-
cles, including purines, 3-methyleneoxindoles, pyrrolo[2,3-d]pyrimidines are especially as-
sociated with kinase inhibitors. 
Whereas kinase inhibitor lead compounds were frequently discovered using high through-
put screening in the past, a much more common current strategy is structure-based rede-
sign of known kinase inhibitor templates, as is evident from the preceding similarity and 
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property comparisons of clinical kinase inhibitors. More recently fragment-based drug dis-
covery has started to play an increasingly important role in the design of kinase inhibitors 
and the first approved kinase inhibitor arrived at by this strategy is vemurafenib.216 A more 
recent example is AZD 5363 (Figure 17).  
Using a virtual screen of fragment compounds (Mr < 250) against a model of AKT based 
on a crystallographic complex of an active form of that protein, followed by crystallography 
of putative binding fragments with a PKA–AKT chimera construct, 7-azaindole was identi-
fied as an AKT hinge-binding fragment (Figure 17a).217 The binding mode of the isoquino-
line-5-sulfonamide AKT inhibitor CCT 077373 discovered earlier218 suggested that deter-
minants for AKT inhibition activity other than hinge binding were a basic amine group 
interacting with acidic groups in the ribose-binding regions, as well as a lipophilic group 
(chlorophenyl) interacting with the G-loop (Figure 17f). For synthetic ease the azaindole 
was replaced with purine, which was arylated at the 6-position to afford benzylamine in-
termediate 1 as one of the most active and ligand-efficient derivatives (Figure 17b). Re-
placement of the phenyl group in that intermediate with piperidine gave rise to compounds 
with improved polar interactions with the acidic residues in the ribose-binding region and 
intermediate 2 (Figure 17c) was identified as a compound with improved activity and ex-
cellent lipophilic ligand efficiency.219 However, this compound was too polar and lacked 
cellular activity. Polarity was modulated by replacement of the azaindole core with pyr-
rolo[2,3-d]pyrimidine, repositioning of the primary amine group, and extension with a 4-
chlorophenyl group to give rise to intermediate 3 (Figure 17d), a highly potent AKT inhibitor 
with well-balanced physicochemical properties.219,220. Intermediate 3 was subsequently 
further elaborated in terms of kinase selectivity, hERG activity, and in vivo disposition 
properties to afford AZD 5363 (Figure 17e).221 
Conclusions 
Kinase inhibitor discovery is a comparatively recent medicinal chemistry endeavour and 
has progressed almost exponentially over the last ~25 years. Whereas early kinase inhib-
itor approvals were for MTKIs, the preponderance of more selective agents has increased 
gradually and now predominates. The advent of kinome-wide kinase assays and associated 
molecular pharmacology technologies, and the ever-expanding knowledge of how kinase 
inhibitors engage their molecular targets at the atomic level, now permit the rational design 
and validation of highly selective agents. This, together with modern clinical investigation 
strategies incorporating patient diagnosis, prognosis, and stratification based on genetic 
and mechanistic biomarkers, will continue to expand the oncologist’s arsenal of highly spe-
cific kinase inhibitor drugs and will hopefully permit truly effective, modular, personalised 
treatments of cancers with less reliance on toxic chemotherapy. Because in general highly 
target-selective agents are also highly specific in vivo, it is hoped that progress can be 
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made to optimise the therapeutic margin (therapeutic versus toxic effects) of kinase inhib-
itor drugs, not only in oncology, but also in other therapeutic indications with unmet med-
ical need. Based on current information it is likely that this may not be achievable in many 
cases with inhibitors that target the catalytic activity of kinases, except in those cases 
where a particular cancer is addicted completely to the activity of a given kinase. In prin-
ciple pharmacological modulation of kinase activities is also possible by allosteric means, 
as we have seen. This is especially attractive if the possibility of such allostery arises in a 
manner that is specific for a particular context in terms of kinase environment and location, 
e.g. through specific disease-associated interactions of a kinases, but such approaches 
remain challenging. Maximisation of kinase inhibitor efficacy by these or other means is 
highly important in order to avoid emergence of drug resistance, which is a feature of many 
current kinase inhibitors, especially those with high target selectivity. As we have seen, 
the first kinase inhibitors for inflammatory disease have now been approved and several 
kinase inhibitors are under clinical investigation in indications other than cancer. A major 
challenge will be to apply what we have learned from oncology kinase inhibitors to other 
major disorders that currently lack effective therapies, such as neurodegeneration and 
(drug-resistant) microbial and viral infections. 
 
Abbreviations. For kinase abbreviations refer to Table S1. Other abbreviations: ALCL, 
anaplastic large cell lymphoma; ALL, acute lymphocytic leukaemia; AML, acute mye-
logenous leukaemia; BCR, B-cell antigen receptor; CLL, chronic lymphocytic leukaemia; 
CML, chronic myelogenous leukaemia; Cssf, concentration of free drug fraction at steady 
state; DLBCL, diffuse large B-cell lymphoma; DFSP, dermatofibroma sarcoma protuberans; 
FDA, U.S. Food and Drug Administration; fot, receptor occupancy as a function of time; 
GIST, gastrointestinal stromal tumour; IPF, idiopathic pulmonary fibrosis; MTC, medullary 
thyroid cancer; MTKI, multi-targeted kinase inhibitor; NHL, non-Hodgkin’s lymphoma; 
NSCLC, non-small cell lung cancer; PH, pleckstrin homology; PIP3, phosphatidylinositol-
3,4,5-trisphosphate; RCC, renal cell carcinoma; RNAPII, RNA polymerase II; SI, selectivity 
index. 
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Figure 1. Historical overview of kinase inhibitor approvals in oncology. 
 
Figure 2. Active and inactive kinase architectures. An active, i.e. catalytically competent, form of PKA (PDB 
entry 1ATP), bound to ATP, Mn2+ (purple spheres; under physiological conditions the corresponding metal cations 
are Mg2+), and a peptide substrate is shown, with key H-bonds indicated as broken black lines. The side chains 
of the Phe (R2) and Asp residues of the DFG motif in the A-loop are shown as sticks. The residues making up the 
regulatory spine are labelled R0 to R4 and the linear arrangement of this spine in active kinase conformations is 
indicated by a broken line (wheat) connecting these residues. This – and subsequent figures showing 3-dimen-
sional protein structures – were constructed using PyMOL (The PyMOL Molecular Graphics System, Version 1.7, 
Schrödinger, LLC.). 
 
Figure 3. Kinase inhibition mechanisms and selectivity. (a) Receptor–ligand interaction mechanisms, 
kinetic parameters, and selectivity indices (adapted from ref.22; refer main text for explanations). (b) Relationship 
between Cssf and on-target fo for type-I kinase inhibitors that all bind a particular on-target kinase with a Kd value 
of 10 nM but that bind an off-target kinase with Kd values of 50 nM (SI1 = 5), 250 nM (SI1 = 25), 1 µM (SI1 = 
100), and 10 µM (SI1 = 1,000). (c) Relationship between time post Cmax and blood levels (Cf) following p.o. 
administration of a kinase inhibitor (Cmax of 10 µM and t½ of 3 h) that interacts with 3 target kinases with variable 
rate constants k4 of 8.5 × 10-3 s-1 (target 1), 2.8 × 10-4 s-1 (target 2), and 1.26 × 10-5 s-1 (target 3) and identical 
k1 of 1 × 108 M-1 s1, k2 of 1 s-1, and k3 of 6 × 10-3 s-1, giving residence times (τ) of 2 min (target 1), 1 h (target 
2), and 22 h (target 3). 
 
Figure 4. Small-molecule kinase inhibitors in the clinic. The numbers of approved agents and those cur-
rently undergoing clinical evaluation is summarised by kinase.  
 
Figure 5. Molecular basis of BCR-ABL resistance. (a) The chemical structures of 1st (imatinib), 2nd (da-
satinib), and 3rd generation (ponatinib) ABL inhibitors. (b) The ABL kinase (green) binding mode of the type-II 
inhibitor imatinib (grey;) shows an H-bond interaction (dashed line) with the gatekeeper residue T315 (yellow; 
secondary mutation sites Y253 & E255 in the Gly-rich loop are indicated in purple).222 (c) The binding of ATP does 
not involve the T351 residue, hence the catalytic competence of the T315I mutant.223 (d) Second-generation 
drugs such as the type-I compound dasatinib are not effective against T315I mutant kinase, as they also make 
polar interactions with T315.224 (e) The recently approved ponatinib, which also inhibits the T315I mutant, evades 
the altered gatekeeper (Ile) through the placement of an ethynyl linkage between its front- and back-pocket 
binding portions.225 Constructed from PDB entries 1IEP, 2SRC, 2GQG, and 3IK3. 
 
Figure 6. Non-ATP-dependent SRC kinase inhibition. (a) The substrate peptide SRC kinase inhibitor KX 01 
was shown by saturation transfer difference NMR spectroscopy, using an ATP site-binding paramagnetic spin-
labelled pyrazolopyrimidine probe containing the 2,2,6,6-tetramethyl-piperidine-1-oxyl (TEMPO) radical, to bind 
to SRC kinases in an ATP non-competitive manner.226 (b) An X-ray crystal structure (PDB entry 3KXZ) of this 
probe (green) bound to the SRC-family kinase LCK (surface with electrostatic potential colouring) is shown. The 
extended substrate-binding cavity, where KX-01 (cyan, modelled (Schrödinger Glide, 
https://www.schrodinger.com/Glide) binding pose) is likely to bind, is evident proximal to the ATP-binding site. 
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Figure 7. Inhibition of EGFR Tyr kinases. (a) Chemical structures of inhibitors. (b) Erlotinib (cyan) is a HER1-
selective inhibitor; it binds to HER1 (grey cartoon; G-loop in blue) with the protein in an active-like conformation, 
with an extended A-loop (yellow) and inward position of the αC-helix (magenta).227 The phenylacetylene group 
of erlotinib interacts with the side chain of M766 (magenta stick model) at the base of the αC-helix, as well as 
the gatekeeper residue T790 (green). (c) Similarly, the HER2-selective compound SYR 127063 binds to HER2 in 
a way that involves an active-like conformation of that protein. Here the ligand trifluoromethylphenyl and chloro 
groups interact with M766 (EGFR numbering) and T790, respectively.228 It is evident that in active HER2 the 
inward position of the αC-helix is less pronounced than in active HER1. In active HER2 the cavity proximal to the 
gatekeeper is thus larger than in active HER1 and can accommodate the larger bis(aryl)ether group of SYR 
127063, whereas the phenylacetylene group of erlotinib would be unable to make contacts with the αC-helix in 
HER2. Conversely the bis(aryl)ether group of SYR 127063 is too large to fit the gatekeeper–αC-helix cavity of 
active EGFR. (d) Dual HER1 and HER2 inhibitors such as lapatinib are generally observed to bind preferentially 
to inactive forms of the protein (HER1 shown), in which a short α-helix in the A-loop supports an outward position 
of the αC-helix.229 (e) TAK 285 is the only EGFR inhibitor for which crystal complexes with both HER1 (ligand and 
coloured protein elements in light colouring) and HER2 (dark colouring) have been solved.228,230 Although similar 
in structure to SYR 127063, TAK 285 inhibits HER1 and HER2 with similar potency. It can be seen that it binds to 
inactive forms of both kinases, which are highly similar. (f) Second-generation type-VI inhibitors are active 
against T790M mutant kinase forms and e.g. afatinib binds to wild-type (ligand and coloured protein elements in 
light colouring) and the T790M form of HER1 (dark colouring) in a very similar manner, with slight repositioning 
of the substituted aniline to optimise interactions with T790 or T790M.68 (g) Osimertinib, on the other hand, is a 
type-VI inhibitor that selectively binds to the T790M mutant EGFR kinase. It was observed that the main deter-
minant for this selectivity in the design of osimertinib was the indole N-methyl group, which can be observed to 
interact closely with the thiomethyl group of M790, an interaction that is not possible with T790 (modelled pose 
from docking using the Schrödinger Glide programme with the covalent docking protocol, using the 3IKA HER1 
structure as the receptor).231 Constructed from PDB entries 1M17, 3PP0, 1XKK, 3POZ, 3RCD, 4G5J, and 4G5P. 
 
Figure 8. Experimental binding modes of FGFR inhibitors. (a) Chemical structures of inhibitors. (b) The 
three clinically most advanced selective FGFR inhibitors AZD 4547 (cyan), infigratinib (magenta), and erdafitinib 
(green) all contain 3,5-dimethoxyphenyl groups that make identical interactions with the kinase. (c) Lucatinib 
(green) and dovitinib (cyan) are MTKIs that also inhibit FGFR kinases with high potency. Lucatinib makes contacts 
with the V561 gatekeeper residue (spheres), whereas dovitinib does not. (d) For this reason dovitinib inhibits 
both wild-type (cyan) and V561M-mutated (green) forms of the kinase, whereas lucatinib is inactive against 
V561M FGFR.89 (e) BLU 9931 (green) is an isoform-selective type-VI FGFR4 inhibitor232 by virtue of targeting 
C552, which is unique in FGFR4 (Tyr in FGFR1-3), whereas FIIN-2233 is a selective dual inhibitor of FGFR and HER 
kinases, both of which contain Cys residues at the same position in the G-loop (C447 in FGFR, C797 in HER). 
Figure constructed from PDB entries 4RWJ, 5EW8, 3TT0, 4RWL, 4RWI, 5AM6, 5AM7, 4XCU, and 4QQC. 
 
Figure 9. Inhibitors of active and inactive forms of MET. (a) Chemical structures of inhibitors. (b) The G-
loop in the N-terminal lobe of the apo-form of MET234 is shown in cyan, the αC-helix, which contains key catalytic 
residues, is shown in magenta, and the A-loop, which is important for substrate recognition, in yellow, with the 
Phe residue of the DFG motif shown as a stick model. An example of an inhibitor that is selective for A-loop-
phosphorylated active form of MET is the derivative of MK 2461. It is a type-I inhibitor and the shape of the ATP-
binding site in its complexed structure (c) is similar to that of the apo-form, except that the G-loop folds over the 
ligand.234 The late-stage development Met inhibitor tivantinib is an unusual type-II inhibitor, which does not bind 
deep into the cavity formed by the DFG-out conformation, but it induces a major shape change in the kinase, 
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involving both the A-loop and the αC-helix (d).235 Like tivantinib, merestinib is selective for unphosphorylated 
inactive MET; it is a conventional type-II inhibitor (e).236 Constructed from PDB entries 3Q6U, 3Q6W, 3RHK, and 
4EEV. 
 
Figure 10. ALK inhibitors. (a) Chemical structures of crizotinib and lorlatinib, a macrocyclic derivative with high 
lipophilic efficiency and CNS bioavailability. (b) Crizotinib (green) and lorlatinib display highly similar ALK binding 
modes (crystallographic water molecules shown as spheres, H-bonds as broken lines).99,237 Constructed from PDB 
entries 2XP2 and 4CLI. 
 
Figure 11. The basis of selectivity of PI3K and mTOR inhibitors. (a) Chemical structures of inhibitors. (b) 
The PI3Kδ-selective idelalisib238 (green) binds to PI3Kδ through H-bonding interactions (broken lines) with the 
backbone amide bonds of the hinge region (cyan). Its selectivity derives predominantly from induced-fit binding 
of the quinazolinone substructure between the side chains of M752 and W760 (spheres). (c) An apo structure of 
PI3Kδ239 shows that the residues that differ between the four PI3K isoforms (magenta) are quite remote from the 
ligand in the PI3Kδ–idelalisib complex (and other ligands in other complexes) and that the slot between the M752 
and W760 residues is closed. Although the residues corresponding to M752 and W760 are conserved in all 4 PI3K 
isoforms, induced-fit binding as observed with idalalisib appears to be a selectivity feature of PI3Kδ-selective 
compounds.239 (d) The PI3Kα-selective alpelisib240 interacts closely (broken lines) with the side chain of Q859, 
one of the few residues around the ATP-binding pocket that are not conserved across the PI3Ks. (e) The pan-
PI3K-selective buparlisip241 binds to PI3Kγ in a similar mode as alpelisib binds to PI3Kδ but any selectivity-
imparting features are absent. (f) The mTOR-selective compound torin 2242 binds to mTOR without any of the 
usual hinge-region H-bonds. Its selectivity is probably due in large part to interaction of the naphthyridinone 
substructure with the indole of W2239 in the hinge, which is not conserved in PI3Ks.243 (g) The dual mTOR- and 
pan-PI3K inhibitor PI 103244 interacts with mTOR through polar interactions involving the morpoline O and the 
phenol OH groups.243 Similar interactions are also possible with any of the PI3K isoforms. Furthermore, PI 103 
adopts an almost completely planar conformation, which can be accommodated in the mTOR and the PI3K ATP-
binding sites, regardless of the width of the binding clefts. Constructed from PDB entries 4XE0, 2WXR, 4JPS, 
3SD5, 4JSX, and 4JT6. 
 
Figure 12. Type-I and type-III AKT inhibitors. (a) AZD 5363 and ipatasertib are type-I inhibitors, whereas 
inhibitor VIII157 and MK 2206 are type-III inhibitors. (b) Compound VIII (salmon) binds to AKT (N-lobe dark cyan, 
C-lobe magenta, PH domain yellow) in an inactive conformation compared to the active state as represented by 
the superposed complex between AMP-PNP (green) and AKT1 (N-lobe light cyan, C-lobe grey). Compound VIII 
binds at a site adjacent to the ATP-binding site composed of portions of the N- and C-lobes, as well as the PH 
domain. Binding induces or stabilises an inactive kinase conformation with disordered αC-helix, altered N- and C-
lobes, and an A-loop conformation that projects the F293 side chain of the DFG motif into the ATP-binding site 
(Phe side chain as spheres). (c) AZD 5363 (magenta) and ipatasertib (cyan) bind to active AKT conformations 
and in complex with AKT occupy the same space as ATP (AMP-PNP; green). MK 2206 (yellow; predominant pose 
obtained from Schrödinger Glide docking shown) probably binds in a very similar manner to AKT as compound 
VIII (salmon). Constructed from PDB entries 3O96, 4EKK, 4EKL, and 4GV1. 
 
Figure 13. Structural basis of MEK inhibition. MEK1 and MEK2 are comparatively unique insofar as these 
kinases contain an allosteric binding site adjacent to, but not overlapping, with the ATP-binding pocket. This 
exosite is evident in ATP/Mg2+-bound structures (a), as well as in complexes with type-I inhibitors (e.g. K252a, 
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b).245 A number of ATP non-competitive MEK inhibitors have been discovered that occupy this exosite, thus 
distorting the catalytic site and inactivating the enzyme (e.g. rafametinib (grey), superposed with ATP (cyan), 
c).246 The 2-fluoro-4-iodo-aniline system of rafametinib has high shape complementarity with the lipophilic back-
pocket of the exosite (d) and is in fact present in most known type-III MEK inhibitors, including 7 of 8 current 
clinical MEK inhibitors (e). Protein structures are shown as green surfaces or meshes; ATP and related nucleosides 
are shown as cyan sticks (Mg2+ as green spheres), allosteric inhibitors as grey sticks, and K252a as yellow sticks. 
Constructed from PDB entries 1S9J, 2P55, 3DV3, 3DY7, 3E8N, 3EQB, 3EQC, 3EQD, 3EQF, 3EQG, 3EQH, 3EQI, 
3MBL, 3ORN, 3OS3, 3PP1, 3SLS, 3V01, 3V04, 4AN2, 4AN3, 4AN9, 4ANB, and 1S9I. 
 
Figure 14. Predicted biopharmaceutical properties of kinase inhibitors compared to all approved 
drugs. According to the Biopharmaceutics Classification System (BCS),247 oral drugs belong to class I if they are 
highly permeable and highly soluble, class II if highly permeable but of low solubility, class III if poorly permeable 
but highly soluble, and class IV if both poorly permeable and soluble. For the purposes of bioequivalence and 
other preclinical and clinical drug development studies class boundaries are based on solubility of the highest 
dose strength and permeability as assessed by pharmacokinetic comparison of oral and intravenous dosing. Here 
an attempt is made to predict such classifications based on calculated solubility (logS derived from intrinsic 
aqueous molar solubility) and permeability (logP; predicted octanol–water partition coefficient). LogS and logP 
values of –4.52 (30 µM) and 1.35, respectively, were used to set the class boundaries.248 It can be seen that 
using this approximation it is predicted that the majority of kinase inhibitors fall into class II, some into class I, 
a few into class III, and very few into class IV. 
 
Figure 15. Chemical similarity of oncology kinase inhibitors and all approved drugs. Dissimilarity was 
calculated using Tanimoto distances based on ChemAxon chemical fingerprints (CF; http://www.che-
maxon.com/jchem/doc/user/). Only inhibitor groups of ≥ 5 compounds are included in the analysis. 
 
Figure 16. Maximum common substructure (MCS) clustering of clinical kinase inhibitors. The chemical 
structures of the 172 experimental kinase inhibitor drugs were submitted to hierarchical MCS clustering using the 
LibMCS programme (www.chemaxon.com). The dendrogram shows that this analysis results in 44 top-level clus-
ters, of which 1 has 5 levels, 10 have 3 levels, 25 have 2 levels, and 7 have 1 level. For top-level clusters 
containing 3 or more common substructures, these are shown. 
 
Figure 17. Fragment-based discovery of the AKT inhibitor AZD 5363. (a) Fragment screening against 
AKT2 identified 7-azapurine as a promising hinge-binding starting point. (b) Fragment growing led to the ben-
zylamine-substituted purine intermediate 1 and (c) replacement of the phenyl group with piperidine afforded the 
hydrophilic intermediate 2. (d) Modulation of polarity and further fragment growing yielded the highly active 
intermediate 3, from which (e) AZD 5363 itself was derived. (f) Fragment growing was guided by the known 
binding mode of the pharmacophorically related isoquinoline-5-sulfonamide CCT 077373. pIC50 values refer to 
AKT2 inhibition. Predicted logP values were calculated using Instant JChem (www.chemaxon.com). Ligand effi-
ciency (LE) was calculated from pIC50 values and lipophilic ligand efficiency (LLE) values were calculated from 
pIC50 and predicted logP.249 Binding mode illustrations were constructed from PDB entries 2JDO, 2UVX, 2UVY, 
2VNW, 2X39, and 4GV1. Ligands are shown as cyan stick models, H-bonds as broken yellow lines, and ligand H-
bonded water molecules as red spheres. Hinge-region residues involved in ligand H-bonding, charged residues in 
the ribose-binding region involved in polar ligand interactions, as well as a mobile Phe residue in the G-loop are 
shown as line models. 
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Table 1. Comparative structural and physicochemical properties of kinase inhibitor experimental drugs.a 
Parameterb 
Oncology kinase 
inhibitorsc 
All approved 
drugsd 
Mr 475 ± 95 (464) 374 ± 121 (351) 
nRot 6.2 ± 2.6 (6) 5.6 ± 3.9 (5) 
HBA 6.1 ± 2.0 (6) 4.7 ± 2.9 (4) 
HBD 2.2 ± 1.0 (2) 1.9 ± 1.9 (1) 
TPSA (Å2) 100 ± 31 (94) 82 ± 54 (73) 
nRing 4.5 ± 1.1 (4) 2.9 ± 1.5 (3) 
nAr 3.4 ± 1.0 (3) 1.6 ± 1.1 (2) 
nChir 0.7 ± 1.8 (0) 2.1 ± 3.0 (1) 
logP 3.4 ± 1.6 (3.5) 2.1 ± 2.8 (2.5) 
logD6.5 2.6 ± 1.7 (2.7) 0.7 ± 3.5 (1.2) 
logS -5.4 ± 1.3 (-5.4) -3.7 ± 2.0 (-3.8) 
aValues are average ± standard deviation (median). bnRot, number of nonterminal rotatable bonds; HBA, number 
of H-bond acceptors; HBA, number of H-bond donors; TPSA, topological polar surface area; nRing, number of 
rings; nAr, number of aromatic rings; nChir, number of chiral centres; log P, predicted octanol–water partition 
coefficient; log D6.5, predicted octanol–water distribution coefficient at pH = 6.5; log S, predicted intrinsic molar 
aqueous solubility. cOncology kinase inhibitors, n = 172; dall approved drugs, n = 1,478 (data from 
http://www.drugbank.ca/), for small-molecule drugs with 200 < Mr < 800, excluding inorganics, neutraceutics, 
and illicit drugs). TPSA, logP, logD, and logS were predicted using the Instant JChem application 
(https://www.chemaxon.com/products/instant-jchem-suite/instant-jchem/).  
 
 49 
 
Figure 1 
 50 
 
Figure 2 
  
 51 
 
Figure 3 
 52 
 
Figure 4 
 53 
 
Figure 5 
 54 
 
Figure 6 
  
 55 
 
Figure 7 
 56 
 
Figure 8 
 57 
 
Figure 9 
  
 58 
 
Figure 10 
 59 
 
Figure 11 
  
 60 
 
Figure 12 
  
 61 
 
Figure 13 
 62 
 
Figure 14 
 63 
 
Figure 15 
 64 
 
Figure 16 
  
 65 
 
Figure 17 
 1 
Table S1. Protein kinase nomenclature. 
Name Abbreviation Synonyms Gene UniProtKB entrya 
Tyrosine-protein kinase ABL1 ABL1 c-Abl ABL1 (ABL, JTK7) P00519 
Tyrosine-protein kinase ABL2 ABL2 ARG ABL2 (ABLL, ARG) P42684 
RAC-alpha serine/threonine-protein kinase, protein kinase B alpha AKT1 PKBα ΑΚΤ1 P31749 
RAC-beta serine/threonine-protein kinase, protein kinase B beta AKT2 PKBβ AKT2 P31751 
ALK tyrosine kinase receptor, anaplastic lymphoma kinase ALK  ALK Q9UM73 
Aurora kinase A, aurora 2 ARK1  AURKA, ARK1, AURA O14965 
Aurora kinase B, aurora 1 ARK2 STK1 AURKB, ARK2, STK1 Q96GD4 
Aurora kinase C, aurora 3 ARK3  AURKC, ARK3 Q9UQB9 
Serine-protein kinase ATM, ataxia telangiectasia mutated ATM  ATM Q13315 
Serine/threonine-protein kinase ATR, ataxia telangiectasia and Rad3-related protein, FRAP-
related protein 1 ATR  ATR, FRP1 Q13535 
Tyrosine-protein kinase receptor UFO, AXL oncogene AXL  AXL, UFO P30530 
Serine/threonine-protein kinase A-Raf A-RAF PKS ARAF1 (PKS, PKS2) P10398 
Serine/threonine-protein kinase B-Raf B-RAF  BRAF1, RAFB1 P15056 
Tyrosine-protein kinase BTK, Bruton tyrosine kinase BTK ATK BTK, AGMX1, ATK, BPK Q06187 
Cell division cycle 7-related protein kinase CDC7   O00311 
Cyclin-dependent kinase 1 CDK1  CDK1, CDC2, CDKN1 P06493 
Cyclin-dependent kinase 2 CDK2  CDK2, CDKN2 P24941 
Cyclin-dependent kinase 4 CDK4  CDK4 P11802 
Cyclin-dependent kinase 6 CDK6  CDK6, CDKN6 Q00534 
Cyclin-dependent kinase 7 CDK7  CDK7, CAK, CDKN7, MO15, STK1 P50613 
Cyclin-dependent kinase 9 CDK9  CDK9, CDC2L4, TAK P50750 
Serine/threonine-protein kinase Chk1, checkpoint kinase-1 CHK1  CHEK1, CHK1 O14757 
Serine/threonine-protein kinase Chk2, checkpoint kinase-2 CHK2  CHEK2, CDS1, CHK2, RAD53 O96017 
Choline kinase alpha CK CHETK-α CHKA, CHK, CKI P35790 
Casein kinase II subunit alpha CK IIα  CSNK2A1, CK2A1 P68400 
RAF proto-oncogene serine/threonine-protein kinase C-RAF RAF-1 RAF1 P04049 
Proto-oncogene tyrosine-protein kinase Src C-SRC  SRC P12931 
Macrophage colony-stimulating factor 1 receptor CSF1R c-Fms CSF1R (FMS) P07333 
DNA-dependent protein kinase catalytic subunit DNA-PKcs DNAPK1, p460 PRKDC, HYRC, HYRC1 P78527 
Epidermal growth factor receptor EGFR ErbB1, HER1 EGFR (ERBB, ERBB1, HER1) P00533 
Receptor tyrosine-protein kinase erbB-2 ERBB2 MLN19, NEU, HER2 ERBB2 (HER2, MLN19, NEU, NGL) P04626 
Receptor tyrosine-protein kinase erbB-3 ERBB3 HER3 ERBB3 (HER3) P21860 
Receptor tyrosine-protein kinase erbB-4 ERBB4 HER4 ERBB4 (HER4) Q15303 
Focal adhesion kinase 1 FADK1  PTK2, FAK, FAK1 Q05397 
Protein-tyrosine kinase 2-beta, focal adhesion kinase 2 FADK2 CADTK PTK2B, FAK2, PYK2, RAFTK Q14289 
Basic fibroblast growth factor receptor 1, Fms-like tyrosine kinase 2 FGFR1 bFGF-R-1, FLT1 FGFR1 P11362 
Fibroblast growth factor receptor 2, Keratinocyte growth factor receptor FGFR2 K-sam FGFR2 P21802 
Fibroblast growth factor receptor 3 FGFR3  FGFR3 P22607 
Fibroblast growth factor receptor 4 FGFR4  FGFR4 P22455 
Receptor-type tyrosine-protein kinase FLT3 FLT3 FLK2, STK1 FLT3 (CD135, FLK2, STK1) P36888 
Hepatocyte growth factor receptor HGFR MET MET P08581 
 2 
Insulin-like growth factor 1 receptor IGF1R  IGFR1 P08069 
Insulin receptor IR CD220 ISNR P06213 
Tyrosine-protein kinase JAK1, Janus kinase 1 JAK1  JAK1 (JAK1A, JAK1B) P23458 
Tyrosine-protein kinase JAK2, Janus kinase 2 JAK2  JAK2 O60674 
Tyrosine-protein kinase JAK3, Janus kinase 3 JAK3 LJAK JAK3 P52333 
Tyrosine-protein kinase Lck, leukocyte C-terminal Src kinase LCK LSK, p56-LCK LCK P06239 
Mitogen-activated protein kinase 1, extracellular signal-regulated kinase 2 MAPK1 ERK2, MAPK2, p42-MAPK MAPK1 P28482 
Mitogen-activated protein kinase 3, extracellular signal-regulated kinase 1 MAPK3 ERK1, MAP2K, p44-MAPK MAPK3 P27361 
Dual specificity mitogen-activated protein kinase kinase 1 MAPKK1 MKK1, MEK1 MAP2K1 (MEK1, PRKMK1) Q02750 
Dual specificity mitogen-activated protein kinase kinase 2 MAPKK2 MEK2 MAP2K2 (MEK2, MKK2, PRKMK2) P36507 
Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38-α MAPK14 p38-α MAPK14, CSBP, MXI2, SAPK2A Q16539 
Maternal embryonic leucine zipper kinase MELK  MELK Q14680 
MAP kinase-interacting serine/threonine-protein kinase 1 MNK1  MKNK1, MNK1 Q9BUB5 
MAP kinase-interacting serine/threonine-protein kinase 2 MNK2  MKNK2, GPRK7, MNK2 Q9HBH9 
Serine/threonine-protein kinase mTOR mTOR mTOR1 MTOR (FRAP, FRAP1, FRAP2, RAFT1, RAPT1) P42345 
Platelet-derived growth factor receptor alpha PDGFRα PDGFR2 PDGFR2 (PDGFR2, RHEPDGFRA) P16234 
Platelet-derived growth factor receptor beta PDGFRβ PDGFR1 PDGFRB (PDGFR, PDGFR1) P09619 
3-Phosphoinositide-dependent protein kinase 1 PDK1 PDPK1 PDPK1 (PDK1) O15530 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PI3Kα p110α PIK3CA P42336 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta isoform PI3Kβ p110β PIK3C1 P42338 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform PI3Kδ p110δ PIK3CD O00329 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PI3Kγ p110γ PI3CG P48736 
cAMP-dependent protein kinase catalytic subunit alpha PKA C-α  PRKACA P17612 
Protein kinase C beta type PKCβ  PRKCB, PKCB P05771 
Serine/threonine-protein kinase pim-1 PIM1  PIM1 P11309 
Serine/threonine-protein kinase pim-2 PIM2  PIM2 Q9P1W9 
Serine/threonine-protein kinase pim-3 PIM3  PIM3 Q86V86 
RAC-alpha serine/threonine-protein kinase, protein kinase B PKB PKBα, c-Akt AKT1 (PKB, RAC) P31749 
Serine/threonine protein kinase PLK1, polo-like kinase 1 PLK1 STPK13 PLK1, PLK P53350 
Serine/threonine protein kinase PLK4, polo-like kinase 4 PLK4 SAK PLK4, SAK O00444 
Proto-oncogene tyrosine-protein kinase receptor Ret RET   P07949 
Rho-associated protein kinase 1 ROCK-I p160ROCK ROCK1 Q13464 
Rho-associated protein kinase 2 ROCK-II p164 ROCK-2 ROCK2 O75116 
Mast/stem cell growth factor receptor Kit SCFR c-Kit KIT (SCFR) P10721 
Serine/threonine-protein kinase SMG1 SMG1  SMG1, ATX, KIAA0421, LIP Q96Q15 
Tyrosine-protein kinase SYK, spleen tyrosine kinase SYK  SYK P43405 
Angiopoietin-1 receptor; tunica interna endothelial cell kinase TEK TIE2  Q02763 
Transforming growth factor-beta receptor type I TGFR1 ALK5, SKR4 TGFBR1 (ALK5, SRK4) P36897 
High affinity nerve growth factor receptor, tropomyosin-related kinase A TRK1 TRKA NTRK1, MTC, TRK, TRKA P04629 
BDNF/NT-3 growth factors receptor, tropomyosin-related kinase B TRK2 TRKB NTRK2, TRKB Q16620 
NT-3 growth factor receptor TRK3 TRKC NTRK3, TRKC Q16288 
Transformation/transcription domain-associated protein TRRAP STAF40 TRRAP, PAF400 Q9Y4A5 
Non-receptor tyrosine-protein kinase TYK2 TYK2  TYK2 P29597 
Vascular endothelial growth factor receptor 1 VEGFR1 FLT1, FRT FLT1 (FLT, FRT, VEGFR1) P17948 
Vascular endothelial growth factor receptor 2 VEGFR2 KDR, FLK1 KDR (FLK1, VEGFR2) P35968 
 3 
Vascular endothelial growth factor receptor 3 VEGFR3 FLT4 FLT4 (VEGFR3) P35916 
Wee1-like protein kinase WEE1 WEE1A WEE1 P30291 
a http://www.uniprot.org/ 
Table S2. BCR-ABL inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Gleevec Imatinib STI 571 Novartis ABL, PDGFR, SCFR, SRC Approved MAY 2001 1 
Sprycel Dasatinib BMS 354825 BMS ABL, mutant ABL, SRC (MTKI) Approved JUN 2006 2 
Tasigna Nilotinib AMN 107 Novartis ABL, mutant ABL, PDGFR, SRC Approved OCT 2007 3 
Bosulif Bosutinib SKI 606 Pfizer ABL, mutant ABL, SRC Approved SEP 2012 4 
Iclusig Ponatinib AP 24534 Ariad ABL, mutant ABL, SRC, VEGFR, PDGFR, FGFR (MTKI) Approved DEC 2012 
5 
Supect Radotinib IY 5511 Il-Yang Pharmaceutical ABL, mutant ABL Approved OCT 2012 (S. Korea) 6 
 Flumatinib  Jiangsu Hansoh Pharmaceutical ABL, mutant ABL, PDGFRF, SCFR, SRC Phase-III 7 
  ABL 001 Novartis ABL  Phase-I 8 
Table S3. SRC kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  KX 01 Thenex & Hanmi SRC Phase-II 9 
 Saracatinib AZD 0530 AstraZeneca SRC, ABL Phase-II 10 
  AZD 0424 AstraZeneca SRC, ABL Phase-I 11 
Table S4. Epidermal growth factor receptor tyrosine kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Iressa Gefitinib AZD 1839 AstraZeneca HER1 Approved JUL 2003 12 
Tarceva Erlotinib OSI 744 OSI HER1 Approved NOV 2004 13 
Tykerb Lapatinib GSK 572016 GSK HER2, HER1 Approved MAR 2007 14 
Conmana Icotinib BPI-2009H BettaPharma HER1, HER2 Approved JUN 2011 (China) 15 
Gilotrif Afatinib BIBW 2992 Boehringer-Ingelheim HER1, HER2, HER4, T790M HER1 Approved JUL 2013 16 
Tagrissa Osimertinib AZD 9291 AstraZeneca T790M HER1 Approved NOV 2015 17 
 Neratinib HKI 272 Puma Biotechnology HER1, HER2, T790M HER1 Phase-III 18 
 Dacomitinib PF 299804 Pfizer HER1, HER2, HER4, T790M HER1 Phase-III 19 
  ASP 8273 Astellas T790M HER1 Phase-III 20 
 Rociletinib CO 1686 Clovis Oncology T790M HER1 Phase-III 21 
 Sapitinib AZD 8931 AstraZeneca HER1, HER2 Phase-II 22 
 Tesevatinib KD 019 Kadmon HER1, T790M HER1 Phase-II 23 
 Varlitinib ASLAN 001 Aslan & Array HER1, HER2 Phase-II 24 
  AZD 3759 AstraZeneca HER1, HER2 Phase-II 25 
 Poziotinib HM781-36B Spectrum & Hanmi Pharmaceu-tical HER1, HER2, HER4, T790M HER1 Phase-II 
26 
  HM 61713 Hanmi Pharmaceuticals & Boehringer Ingelheim T790M HER1 Phase-II 
27 
  EGF 816 Novartis T790M HER1 Phase-II 28 
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 Tarloxotinib TH 4000 Threshold Pharmaceuticals HER1, HER2, T790M HER1 Phase-II 29 
  S 222611 Shionogi HER1, HER2, HER4 Phase-I 30 
 Tucatinib ONT 380 Oncothyreon HER2 Phase-I NCT02614794 
  PF 06747775 Pfizer T790M HER1 Phase-I NCT02349633 
 Epitinib HMPL 813 Hutchison MediPharma HER1 Phase-I 31 
 Theliatinib HMPL 309 Hutchison MediPharma HER1 Phase-I NCT02601274 
 Avitinib  Acea Bio (Hangzhou) T7980M HER1 Phase-I 32 
 Pyrotinib  Jiangsu HengRui  HER1, HER2 Phase-I 33 
 Pirotinib KBP 5209 SihuanPharm HER1, HER2, T790M HER1 Phase-I NCT02442414 
Table S5. Inhibitors of tyrosine kinases in the CSF-1/PDGF receptor subfamily. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Sutent Sunitinib SU 11248 Pfizer VEGFR, PDGFR, FLT3, SCFR, RET (MTKI) Approved JAN 2006 
34 
Votrient Pazopanib GW 786034B GSK VEGFR, PDGFR, FGFR, SCFR, FMS (MTKI) Approved OCT 2010 
35 
Caprelsa  Vandetanib  AZD 6474 AstraZeneca VEGFR, EGFR, PDGFR, FGFR, RET (MTKI) Approved APR 2011 
36 
Inlyta Axitinib AG 013736 Pfizer VEGFR, PDGFR, SCFR (MTKI) Approved JAN 2012 37 
Stivarga Regorafenib BAY 73-4506 Bayer VEGFR, SCFR, RAF, PDGFR, FGFR, KIT (MTKI) Approved SEP 2012 
38 
Vargatef (Ovef) Nintedanib BIBF 1120 Boehringer-Ingelheim VEGF, PDGF, FGFR (MTKI) Approved NOV 2014 39 
Lenvima Lenvatinib E 7080 Eisai VEGFR, FGFR, PDGFR, SCFR, RET (MTKI) Approved FEB 2015 
40 
 Midostaurin PKC 412 Novartis FLT3 (MTKI) Phase-III 41 
Masivet Masitinib AB 1010 AB-Science KIT, PDGFR, SCFR, FGFR (MTKI) Phase-III 42 
 Tivozanib AV 951 Aveo & Kyowa Hakko Kirin VEGFR (MTKI) Phase-III 43 
 Motesanib AMG 706 Amgen & Millenium-Takeda VGFR, PDGFR, SCFR (MTKI) Phase-III 44 
 Crenolanib CP 868,596 Arog PDGFR, SCFR, FLT3 (selective) Phase-III 45 
 Fruquintinib HMPL 013 Hutchison MediPharma VEGFR (selective) Phase-III 46 
 Quizartinib AC 220 Daiichi FLT3 (selective) Phase-III 47 
Recentin Cediranib AZD 2171 AstraZeneca VEGFR, PDGFR (selective) Phase-III 48 
 Pexidartinib PLX 3397 Daiichi & Plexxikon CSF1R, SCFR, FLT3 (selective) Phase-III 49 
 Sulfatinib HMPL 012 Hutchison MediPharma VEGFR, FGFR Phase-III NCT02589821 
 Apatinib YN 968D1 LSK BioPharma VEGF Phase-II 50 
 Lucitanib E 3810 Clovis Oncology & Servier VEGFR, CSF1R, FGFR (selective) Phase-II 51 
  X 82 Tyrogenex VEGFR, PDGFR Phase-II NCT02146222 
 Anlotinib AL 3818 Advenchen VEGFR, FGFR Phase-II NCT02649361 
  AKN-028 Akinion FLT3 (selective) Phase-II 52 
 Linifanib ABT 869 Abbott VEGFR, FLT3 (MTKI) Phase-I 53 
  PLX 9486 Plexxikon KIT Phase-I NCT02401815 
  PLX 7486 Plexxikon & Daiichi Sankyo FLT3, pan-TRK Phase-I NCT01804530 
  ARRY 382 Array CSF1R Phase-I 54 
 Dovitinib TKI 258 Novartis VEGFR, FLT3, FGFR (MTKI) Phase-I 55 
 Sitravatinib MGCD 516 Mirati MTKI Phase-I 56 
 Tafetinib SIM 010603 Nanjing Yoko Biomedical MTKI Phase-I 57 
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Table S6. Fibroblast growth factor receptor kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  AZD 4547 AstraZeneca Pan-FGFR Phase-II 58 
 Infigratinib BGJ 398 Novartis pan-FGFR Phase-II 59 
 Erdafitinib JNJ 42756493 Jansen pan-FGFR Phase-II 60 
  E 7090 Eisai pan-FGFR Phase-I 61 
  BAY 1163877 Bayer pan-FGFR Phase-I 62 
  ARQ 087 ArQule FGFR Phase-I 63 
  INCB 054828 Incyte FGFR Phase-I 64 
  PRN 1371 Principia Biopharma FGFR Phase-I 65 
  FGF 401 Novartis FGFR4 Phase-I NCT02325739 
  TAS 120 Taiho Pharmaceutical pan-FGFR Phase-I 66 
Table S7. Hepatocyte growth factor receptor kinase (MET) inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Cometriq Cabozantinib XL 184 Exelixis MET, RET, VEGFR Approved NOV 2012 67 
 Tivantinib ARQ 197 ArQule & Daiichi MET Phase-III 68 
 Foretinib GSK 1363089 GSK & Exelixis MET, VEGFR Phase-II 69 
  ASLAN 002 Aslan MET Phase-II 70 
  MGCD 265 Mirati MET (MTKI) Phase-II NCT02544633 
 Savolitinib AZD 6094 AstraZeneca & Hutchison Me-diPharma MET Phase-II 
71 
 Tepotinib EMD 1214063 Merck Serono MET Phase-II 72 
  AMG 337 Amgen MET Phase-II 73 
 Capmatinib INC 280 Novartis & Incyte MET Phase-II 74 
 Merestinib LY 2801653 Eli Lilly MET (MTKI) Phase-II 75 
 Altiratinib DCC 2701 Deciphera MET (MTKI) Phase-I 76 
  SAR 125844 Sanofi MET Phase-I 77 
Table S8. ALK tyrosine kinase receptor inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Xalkori Crizotinib PF 02341066 Pfizer ALK (c-MET) Approved AUG 2011 78 
Zykadia Ceritinib LDK 378 Novartis ALK Approved APR 2014 79 
Alecensa Alectinib AF-802 Roche ALK Approved DEC 2015 80 
 Brigatinib AP 26113 Ariad ALK (HER) Phase-III 81 
 Lorlatinib PF 06463922 Pfizer ALK (ROS1) Phase-II 82 
 Belizatinib TSR 011 Tesaro ALK Phase-II NCT02048488 
Table S9. TRK inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Entrectinib RXDX 101 Ignyta & Nerviano Medical Sciences Pan-TRK (ROS1, ALK) Phase-II 
83 
  LOXO 101 Loxo Oncology & Array Pan-TRK Phase-II 84 
  DS 6051b Daiichi Sankyo Pan-TRK (ROS1) Phase-I NCT02279433 
 
 6 
Table S10. AXL inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Gilteritinib ASP 2215 Astellas AXL, FLT3 Phase-III 85 
  BGB 324 BerGenBio AXL Phase-I 86 
Table S11. TGFR kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Galunisertib LY2157299 Eli Lilly TGFR1 Phase-II 87 
  TEW 7197 MedPacto TGFR1 Phase-I 88 
Table S12. JAK2 kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Jakafi Ruxolitinib INC 424 Novartis & Incyte JAK2 Approved NOV 2011 89 
 Pacritinib SB 1518 CTI BioPharma JAK2 (FLT3) Phase-III 90 
  NS-018 Nippon Shinyaku JAK2 Phase-II 91 
 Momelotinib CYT 387 Gilead JAK1, JAK2 Phase-III 92 
 Cerdulatinib PRT 062070 Portola JAK (SYK) Phase-II 93 
  INCB 052793 Incyte JAK1 Phase-I 94 
  INCB 039110 Incyte JAK1 Phase-I 95 
Table S13. Bruton kinase BTK inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Imbruvica Ibrutinib PCI-32765 Pharmacyclics BTK Approved NOV 2013 96 
 Acalabrutinib ACP 196 AstraZeneca BTK Phase-III 97 
  HM 71224 Hanmi Pharmaceutical & Eli Lilly BTK Phase-I NCT01765478 
  GS 4059 Gilead BTK Phase-I 98 
  BGB 3111 BeiGene BTK Phase-I 99 
  PRN 1008 Principia Biopharma BTK Phase-I 65 
Table S14. Focal adhesion kinase 1 inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  GSK 2256098 GSK FAK Phase-II 100 
 Defactinib VS 6063 Verastem FAK, PYK2 Phase-II 101 
  VS 4718 Verastem FAK Phase-I 102 
Table S15. SYK inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Entospletinib GS-9973 Gilead SYK Phase-II 103 
  TAK 659 Millenium SYK Phase-I 104 
Table S16. Phosphatidylinositol-3-kinase pathway inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Torisel Temsirolimus  CCI 779 Pfizer mTOR Approved MAY 2007 105 
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Afinitor Everolimus RAD001 Novartis mTOR Approved MAR 2009 106 
Zydelig Idelalisib GS 1101 Gilead PI3Kδ Approved JUL 2014 107 
 Duvelisib INK 1197 Infinity & AbbVie PI3Kδ, PI3Kγ Phase-III 108 
 Buparlisib BKM 120 Novartis Pan-PI3K Phase-III 109 
 Alpelisib BYL 719 Novartis PI3Kα Phase-III 110 
 Copanlisib BAY 80-6946 Bayer Pan-PI3K Phase-III 111 
 Taselisib GDC 0032 Genentech PI3Kα Phase-III 112 
 Voxtalisib XL 765 Exelixis, Sanofi Pan-PI3K, mTOR Phase-II 113 
 Vistusertib AZD 2014 AstraZeneca mTOR Phase-II 114 
  SF 1126 SignalRX Pharmaceuticals PI3K (MTKI) Phase-II 115 
 Sapanisertib MLN 0128 Millenium mTOR Phase-II 116 
  AMG 319 Amgen PI3Kδ Phase-II 117 
  CC 223 Celgene mTOR Phase-II 118 
  CC 115 Celgene mTOR (DNA-PK) Phase-II 119 
  GSK 2636771 GSK PI3Kβ Phase-II 120 
  CUDC 907 Curis PI3K (HDAC) Phase-II 121 
  LY 3023414 Eli Lilly Pan-PI3K, mTOR Phase-II 122 
  PQR 309 Piqur mTOR, PI3K Phase-II NCT02723877 
 Pictilisib GDC-0941 Genentech PI3K Phase-I 123 
 Gedatolisib PF-05212384 Pfizer PI3K, mTOR Phase-I 124 
  ZSTK 474 Zenyaku Kogyo PI3K Phase-I 125 
  MLN 1117 Millenium PI3Kα Phase-I NCT02625259 
  AZD 8186 AstraZeneca PI3Kβ, PI3Kδ Phase-I 126 
  AZD 8835 AstraZeneca PI3Kα, PI3Kδ Phase-I 127 
  HMPL 689 Hutchison MediPharma PI3Kδ Phase-I NCT02631642 
  INCB 050465 Incyte PI3Kδ Phase-I 128 
  VS 5584 Verastem Pan-PI3K, mTOR Phase-I 129 
  KA 2237 Karus Therapeutics PI3Kβ, PI3Kδ Phase-I NCT02679196 
  CDZ 173 Novartis PI3Kδ Phase-I NCT02435173 
Table S17. RAC-alpha serine/threonine-protein kinase, protein kinase B inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  AZD 5363 AstraZeneca & Astex AKT Phase-II 130 
 Ipatasertib GDC 0068 Genentech & Array AKT Phase-II 131 
  LY 2780301 Lilly AKT (p70S6) Phase-II 132 
 Afuresertib ASB 183 Novartis Pan-AKT  Phase-II 133 
  ARQ 092 ArQule AKT Phase-I 134 
  MK 2206 Merck AKT Phase-I 135 
  M 2698 Merck Serono AKT (p70S6) Phase-I NCT01971515 
  AT 13148 Astex AKT (MTKI) Phase-I 136 
  BAY 1125976 Bayer AKT1, AKT2 Phase-I 137 
Table S18. PIM inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  PIM 447 (LGH 447) Novartis Pan-PIM Phase-I 138 
  INCB 053914 Incyte PIM Phase-II 139 
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Table S19. RAF kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Nexavar Sorafenib BAY 43-9006 Bayer & Onyx RAF (MTKI) Approved DEC 2005 140 
Zelboraf Vemurafenib PLX 4032 Plexxikon & Roche Mutant BRAF Approved AUG 2011 141 
Tafinlar Dabrafenib GSK 2118436 GSK ARAF, BRAF, CRAF  Approved MAY 2013 142 
 Encorafenib LGX 818 Novartis & Array Mutant RAF Phase-III 143 
  PLX 8394 Plexxikon & Daiichi Sankyo Mutant B-RAF Phase-II 144 
  RXDX 105 Ignyta RAF (RET) Phase-I 145 
  MLN 2480 Millenium RAF Phase-I 146 
  HM 95573 Hanmi Pharmaceutical Pan-RAF Phase-I NCT02405065 
  LY 3009120 Eli Lilly Pan-RAF Phase-I 147 
  BGB 283 Merck Serono & BeiGene Pan-RAF Phase-I 148 
Table S20. Mitogen-activated protein kinase kinase kinase (MEK) inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Mekinist Trametinib GSK 1120212 GSK MEK1, MEK2 Approved MAY 2013 149 
Cotellic Cobimetinib GDC 0973 Genentech & Exelixis  MEK Approved NOV 2015 150 
 Selumetinib AZD 6244 Array & AZ MEK1, MEK2 (AKT) Phase-III 151,152 
 Binimetinib MEK 162 Novartis & Array MEK1, MEK2 Phase-III 153 
 Refametinib BAY 869766 Bayer & Ardea MEK Phase-II 154 
 Pimasertib AS703026 Merck Serono MEK Phase-II 155 
  PD 325901 Pfizer MEK Phase-II 156 
  TAK 733 Millenium-Takeda MEK Phase-I 157 
  RG 7304 Roche MEK1 (pan-RAF) Phase-I  158 
  E 6201 Strategia Therapeutics MEK Phase-I 159 
Table S21. ERK inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Ulixertinib BVD 523 BioMed Valley Discoveries ERK1, ERK2 Phase-II 160 
  GDC 0994 Genentech & Array ERK1, ERK2 Phase-I 161 
  CC 90003 Celgene ERK Phase-I NCT02313012 
Table S22. p38 MAP kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Ralimetinib LY 2228820 Lilly p38 MAPK Phase-II 162 
 Pexmetinib ARRY-614 Array p38 MAPK Phase-I 163 
Table S23. Cyclin-dependent kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
Ibrane Palbociclib PD 332991 Pfizer CDK4, CDK 6 Approved FEB 2015 164 
 Ribociclib LEE 011 Astex & Novartis CDK4, CDK6 Phase-III 165 
 Abemaciclib LY 2835219 Eli Lilly CDK4, CDK6 Phase-III 166 
 Dinaciclib SCH 727965 Merck CDK1, CDK2, CDK5, CDK9 Phase-II 167 
  AT 7519 Astex Pan-CDK Phase-II 168 
 Milciclib PHA 848125 Nerviano Medical Sciences & Tiziana Life Sciences CDK1, CDK2, CDK4 (TRKA) Phase-II 
169 
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 Alvocidib HMR 1275 Tolero Pharmaceuticals CDK9, pan-CDK Phase-II 170 
 Roniciclib BAY 1000394 Bayer Pan-CDK Phase-II 171 
  TG 02 Tragara CDKs and JAK2, FLT3, ERK5 (MTKI) Phase-I 172 
  RGB 286638 Agennix CDK, MTKI Phase-I 173 
  BAY 1143572 Bayer CDK9 Phase-I 174 
  CYC 065 Cyclacel Pan-CDK Phase-I 175 
Table S24. Aurora kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Alisertib MLN 8237 Millenium-Takeda ARK-A Phase-III 176 
  ENMD 2076 CASI Pharmaceuticals ARK (MTKI) Phase-II 177 
 Ilorasertib ABT 348 AbbVie ARK (MTKI) Phase-II 178 
 Danusertib PHA 739358 Nerviano Medical Sciences Pan-ARK (ABL) Phase-II 179 
 Barasertib AZD 2811 Bind Therapeutics & Astra-Zeneca ARK-B Phase-I 
180 
  TAS 119 Taiho Pharma ARK-A Phase-I 181 
Table S25. Polo-like kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase target Development stage Refs. 
 Volasertib BI 6727 Boehringer-Ingelheim PLK1 Phase-III 182 
  CFI 400945 University Health Network, Toronto PLK4 Phase-I 
183 
Table S26. Checkpoint kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Prexasertib LY 2606368 Eli Lilly & Array CHK1 Phase-II 184 
  GDC 0575 Genentech CHK1 Phase-I 185 
Table S27. ATR inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  VX 970 Vertex ATR Phase-II 186 
  VX 803 Vertex ATR Phase-I NCT02278250 
  AZD 6738 AstraZeneca ATR Phase-I 187 
Table S28. DNAPK inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
  VX 984 Vertex DNAPK Phase-I NCT02644278 
  M 3814 Merck Serono DNAPK Phase-I NCT02316197 
Table S29. New first-in-class kinase inhibitors. 
Proprietary name USAN / INN Corporate code Sponsor Main kinase targets Development stage Refs. 
 Linsitinib OSI 906 Astellas IGF-1R & IR Phase-III 188 
  AZD 1775 AstraZeneca WEE1 Phase-II 189 
 Silmitasertib CX 4945 Senhwa Biosciences CK2 Phase-II 190 
 Amcasertib BBI 503 Boston Biomedical Cancer stem cell pathway kinases Phase-II 191 
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  TCD-717 TCD Pharma CK Phase-I 192 
  TAK 931 Millenium CDC7 Phase-I NCT02699749 
  LXS 196 Novartis PKC Phase-I NCT02601378 
  AR 12 Arno Therapeutics PDK1 Phase-I 193 
  AZD 0156 AstraZeneca ATM Phase-I NCT02588105 
  BAY 1143269 Bayer MNK1 Phase-I 194 
  OTS 167 OncoTherapy Science MELK Phase-I 195 
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